<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS189365</article-id><article-id pub-id-type="doi">10.1101/2023.10.06.561183</article-id><article-id pub-id-type="archive">PPR738055</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">2</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Hierarchy of Psychedelic Effects: Three Systematic Reviews and Meta-Analyses</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shinozuka</surname><given-names>Kenneth</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Jerotic</surname><given-names>Katarina</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mediano</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Alex T.</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Preller</surname><given-names>Katrin H.</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Carhart-Harris</surname><given-names>Robin</given-names></name><xref ref-type="aff" rid="A8">8</xref><xref ref-type="aff" rid="A9">9</xref><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Kringelbach</surname><given-names>Morten L.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A11">11</xref></contrib></contrib-group><aff id="A1"><label>1</label>Centre for Eudaimonia and Human Flourishing, Linacre College, University of Oxford, Oxford, OX3 9BX, UK</aff><aff id="A2"><label>2</label>Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK</aff><aff id="A3"><label>3</label>Oxford Mathematics of Consciousness and Applications Network (OMCAN), University of Oxford, Oxford, OX2 6GG, UK</aff><aff id="A4"><label>4</label>Department of Computing, Imperial College London, London, SW7 2RH, UK</aff><aff id="A5"><label>5</label>Department of Statistics and Data Science (Alumnus), The Wharton School, University of Pennsylvania, Philadelphia, PA 19104, USA</aff><aff id="A6"><label>6</label>Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT 06511, USA</aff><aff id="A7"><label>7</label>Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, Zurich, 8032, Switzerland</aff><aff id="A8"><label>8</label>Centre for Psychedelic Research, Imperial College London, London, SW7 2AZ, UK</aff><aff id="A9"><label>9</label>Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA</aff><aff id="A10"><label>10</label>Department of Neurology, Psychiatry and Behavioral Sciences, University of California, San Francisco, CA 94143, USA</aff><aff id="A11"><label>11</label>Center for Music in the Brain, Department of Clinical Medicine, Aarhus University, Aarhus, 8000, Denmark</aff><author-notes><corresp id="CR1">
<label>*</label>Corresponding <email>kenneth.shinozuka@psych.ox.ac.uk</email> Corresponding address: Centre for Eudaimonia and Human Flourishing, 7 Stoke Place, Headington, Oxford, UK OX3 9BX</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>11</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>07</day><month>10</month><year>2023</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nd/4.0/">CC BY-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Serotonergic psychedelics induce altered states of consciousness and have shown potential in treating a variety of neuropsychiatric disorders, including depression and addiction. Yet their modes of action are currently not fully understood. Here, we provide three systematic reviews and meta-analyses of three hierarchical levels relevant to the effects of psychedelics, i.e., 1) subjective experience (phenomenology), 2) whole-brain neuroimaging and 3) molecular pharmacology. Phenomenologically, medium and high doses of LSD yield significantly higher ratings of visionary restructuralisation than psilocybin on the 5-dimensional Altered States of Consciousness Scale. Our neuroimaging results reveal that psychedelics significantly strengthen between-network functional connectivity (FC) while diminishing within-network FC. Pharmacologically, we found no significant between-drug differences in the selectivity of psychedelics for the 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, or D<sub>2</sub> receptors, relative to the 5-HT<sub>1A</sub> receptor, but we did observe that LSD induces significantly more inositol phosphate formation at the 5-HT<sub>2A</sub> receptor than DMT and psilocin. Our meta-analyses link each of the classic psychedelics – DMT, LSD, and psilocybin – to specific neural fingerprints at each level of the tripartite hierarchy. The results show a highly non-linear relationship between these fingerprints. Overall, the results point to the need for standardising experimental procedures and analysis techniques, as well as for more research on the emergence between different levels of psychedelic effects. Future work could use our tripartite hierarchy framework to investigate the dose-dependent effects of different psychedelics in the same participants.</p></abstract><kwd-group><kwd>psychedelics</kwd><kwd>ayahuasca</kwd><kwd>LSD</kwd><kwd>psilocybin</kwd><kwd>meta-analysis</kwd><kwd>fMRI</kwd><kwd>functional connectivity</kwd><kwd>BOLD activation</kwd><kwd>pharmacology</kwd><kwd>receptor affinity</kwd><kwd>receptor agonism</kwd><kwd>phenomenology</kwd><kwd>subjective experience</kwd><kwd>consciousness</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><label>Section 1</label><title>Introduction</title><p id="P2">Psychedelics have been utilised by early cultures for millennia within diverse sociocultural contexts, as well as spiritual and healing rituals (<xref ref-type="bibr" rid="R48">Garcia &amp; Maia, 2022</xref>; <xref ref-type="bibr" rid="R92">Nichols, 2016</xref>; <xref ref-type="bibr" rid="R135">Tupper et al., 2015</xref>). Western research into psychedelics, having blossomed in the ‘50s and ‘60s following the first study of lysergic acid diethylamide (LSD) in 1947 (<xref ref-type="bibr" rid="R122">Stoll, 1947</xref>), came to a halt in the late 1960s due to changes in government regulations and the classification of these substances as “drugs of abuse” with “no recognised medical value” (<xref ref-type="bibr" rid="R135">Tupper et al., 2015</xref>). Revitalisation of psychedelic research commenced in the 1990s (<xref ref-type="bibr" rid="R63">Hermle et al., 1992</xref>; <xref ref-type="bibr" rid="R123">Strassman et al., 1994</xref>; <xref ref-type="bibr" rid="R123">Strassman &amp; Qualls, 1994</xref>), with three key factors inspiring the current interest: scientific advances, evidence of therapeutic potential, and increased public interest (<xref ref-type="bibr" rid="R1">Aday et al., 2021</xref>). Researchers have come to recognise that psychedelics may be effective tools in the treatment of psychiatric disorders such as depression (<xref ref-type="bibr" rid="R90">Muttoni et al., 2019</xref>; <xref ref-type="bibr" rid="R95">Nutt et al., 2020</xref>) and addiction (<xref ref-type="bibr" rid="R134">Tófoli &amp; de Araujo, 2016</xref>).</p><p id="P3">The effects of psychedelic substances have been examined at several levels. Pharmacological research has measured their interaction with various receptors in the brain (e.g. <xref ref-type="bibr" rid="R52">Glennon et al., 1984</xref>; <xref ref-type="bibr" rid="R149">Watts et al., 1995</xref>), while other research domains have explored the subjective experience of a psychedelic ‘trip’. Neuroimaging research has examined changes in brain activity and functional connectivity under the influence of psychedelics, yet there are still relatively few studies and a plethora of different analysis techniques. Here, we report the findings of a systematic meta-analysis focused on synthesising the evidence from three classic psychedelics: DMT, LSD, and psilocybin. The main aim is to provide an overview and analysis of the literature across three levels of description: (1) phenomenology—to discuss key differences in the states of consciousness induced by these psychedelics; (2) functional neuroimaging—to compare the changes in brain activity, functional connectivity, and entropy that are induced by psychedelics; and (3) pharmacology—to discuss the binding affinities and functional activity of psychedelics with respect to various neural receptors.</p><sec id="S2"><label>Section 1.1</label><title>Phenomenology</title><p id="P4">Psychedelics produce altered states of consciousness that are characterised by ego death, or a breakdown in one’s sense of self, and “mystical” experiences (<xref ref-type="bibr" rid="R56">Griffiths et al., 2018</xref>; <xref ref-type="bibr" rid="R152">Yaden et al., 2021</xref>). Mystical experiences on psychedelics can be defined by four components: a sense of unity and sacredness; transcendence of time and space; positive mood; and ineffability (<xref ref-type="bibr" rid="R10">Barrett et al., 2015</xref>; <xref ref-type="bibr" rid="R81">Maclean et al., 2012</xref>). Individuals who have taken one of the classic psychedelics are significantly more likely to have had a full mystical experience than people who had other kinds of meaningful experiences (<xref ref-type="bibr" rid="R55">Griffiths et al., 2019</xref>).</p><p id="P5">However, perhaps the strongest predictor of therapeutic outcomes from psychedelic research is so-called ‘emotional breakthrough’ experiences, as assessed by the emotional breakthrough inventory or EBI (<xref ref-type="bibr" rid="R114">Roseman et al., 2019</xref>). Additionally, psychological insight, which includes awareness of previously repressed emotions (<xref ref-type="bibr" rid="R31">Davis et al., 2021</xref>; <xref ref-type="bibr" rid="R99">Peill et al., 2022</xref>), correlates with the therapeutic effects of psychedelics.</p><p id="P6">These experiential themes – insight, mystical experiences, and ego dissolution – are all captured by the Altered States of Consciousness (ASC) scale. The 5D-ASC measures altered states of consciousness along five different dimensions: oceanic boundlessness (e.g. a sense of interconnectedness), anxious ego dissolution, visionary restructuralisation (e.g. visual hallucinations), auditory alterations, and reduction of vigilance. Subsequent factor analyses led to the extraction of 11 lower-order dimensions from the 5D-ASC, resulting in the development of the 11D-ASC: experience of unity, spiritual experience, blissful state, insightfulness, disembodiment, impaired control and cognition, anxiety, elementary imagery, complex imagery, audio-visual synesthesia, and changed meaning of percepts (<xref ref-type="bibr" rid="R126">Studerus et al., 2010</xref>). Because the ASC is the most common subjective questionnaire in the literature on the neuroimaging of psychedelics, we performed a meta-analysis on both the 5D- and 11D-ASC scores of DMT, LSD, and psilocybin.</p><p id="P7">However, the ASC is just one of many scales for rating the subjective effects of psychedelics. The multiplicity of scales makes it difficult to comprehensively evaluate the literature on the phenomenology of psychedelics. To date, only two studies have used a single set of scales to compare the subjective effects of LSD and psilocybin in the same group of participants (<xref ref-type="bibr" rid="R65">Holze et al., 2022</xref>; <xref ref-type="bibr" rid="R77">Ley et al., 2023</xref>). More recent research has attempted to draw direct comparisons by qualitatively examining larger datasets, such as the Erowid corpus of trip reports (<xref ref-type="bibr" rid="R8">Ballentine et al., 2022</xref>; <xref ref-type="bibr" rid="R26">Coyle et al., 2012</xref>; <xref ref-type="bibr" rid="R106">Qiu &amp; Minda, 2021</xref>; <xref ref-type="bibr" rid="R116">Sanz et al., 2018</xref>; <xref ref-type="bibr" rid="R153">Zamberlan et al., 2018</xref>). The key findings from these comparative studies are discussed in <xref ref-type="supplementary-material" rid="SD1">Section S3</xref>.</p></sec><sec id="S3"><label>Section 1.2</label><title>Neuroimaging</title><p id="P8">After a long pause in psychedelic research on humans, the pioneering positron emission tomography (PET) scans by Vollenweider and Gouzoulis-Mayfrank in the late 1990s ushered in a new era of research on the human brain under psychedelics (<xref ref-type="bibr" rid="R54">Gouzoulis-Mayfrank et al., 1999</xref>; <xref ref-type="bibr" rid="R143">Vollenweider et al., 1997</xref>, <xref ref-type="bibr" rid="R145">1999</xref>). Forty to fifty years after the initial spate of electroencephalography (EEG) studies on psychedelics (see <xref ref-type="bibr" rid="R128">Tagliazucchi (2020)</xref> for a review), several studies used EEG to measure human brain activity under psychedelics, especially ayahuasca (<xref ref-type="bibr" rid="R64">Hoffmann, 2001</xref>; <xref ref-type="bibr" rid="R109">Riba, Anderer, et al., 2002</xref>; <xref ref-type="bibr" rid="R108">Riba et al., 2004</xref>; <xref ref-type="bibr" rid="R109">Riba, Rodríguez-Fornells, et al., 2002</xref>; <xref ref-type="bibr" rid="R125">Stuckey et al., 2005</xref>) and psilocybin (<xref ref-type="bibr" rid="R137">Umbricht et al., 2002</xref>, <xref ref-type="bibr" rid="R138">2003</xref>). However, many of these studies were predicated on the notion that psychedelics are principally useful as a model for psychosis and schizophrenia. For instance, <xref ref-type="bibr" rid="R143">Vollenweider et al. (1997)</xref> considered the feeling of ego dissolution on psychedelics to be a model of psychosis. However, the last decade has seen a huge rise in more explorative, data-driven or hypothesis-free neuroimaging studies on psychedelics, as well as studies on their therapeutic benefits for clinical populations, e.g. patients with depression. The first functional neuroimaging study of psychedelics, published in 2012 (<xref ref-type="bibr" rid="R21">Carhart-Harris, Erritzoe, et al., 2012</xref>), was an exploratory analysis of psilocybin-induced changes in cerebral blood flow and BOLD activity in healthy human participants. Since then, dozens of fMRI studies have been performed on human participants under the influence of ayahausca, LSD, psilocybin and DMT, including several studies on depressed patients (<xref ref-type="bibr" rid="R24">Carhart-Harris et al., 2017</xref>; <xref ref-type="bibr" rid="R32">Daws et al., 2022</xref>; <xref ref-type="bibr" rid="R41">Doss et al., 2021</xref>; <xref ref-type="bibr" rid="R83">Mertens et al., 2020</xref>; <xref ref-type="bibr" rid="R113">Roseman et al., 2018</xref>; <xref ref-type="bibr" rid="R147">Wall et al., 2022</xref>). Additionally, in the last decade, two studies collected primary magnetoencephalography (MEG) data on healthy human participants who had been administered LSD and psilocybin (<xref ref-type="bibr" rid="R23">Carhart-Harris et al., 2016</xref>; <xref ref-type="bibr" rid="R89">Muthukumaraswamy et al., 2013</xref>).</p><p id="P9">We chose to perform a meta-analysis exclusively on the fMRI data and not on any of the other modalities used to measure brain activity. There were too few primary PET (4), SPECT (4), or MEG (2) datasets to merit a meta-analysis; by comparison, 30 fMRI studies have collected original data. While there are many more primary EEG datasets (25) from the post-1960s era (and even more from the 1950s-1960s era) than PET, SPECT, or MEG, most of the EEG studies do not spatially localise the brain activity recorded at EEG electrodes. Without the raw data, which may be difficult to access when some of the studies are nearly 20 years old, we cannot source-localise the EEG activity ourselves. On the other hand, the published fMRI data on psychedelics tends to report the specific coordinates of brain regions that become more or less active under psychedelics. In general, EEG has higher temporal resolution than fMRI (<xref ref-type="bibr" rid="R61">Haufe et al., 2018</xref>), so a future meta-analysis that focuses on the temporal, rather than spatial, characteristics of brain activity on psychedelics could consider the EEG rather than fMRI data.</p><p id="P10">The fMRI studies assess three different metrics of brain activity: BOLD activation, connectivity, and entropy. Studies on BOLD activation analyse changes in the trajectory of BOLD timeseries with a rapidly-acting psychedelic, e.g. intravenously-administered psilocybin. Connectivity studies can examine undirected, instantaneous correlations between different regions (a type of functional connectivity) or model the experimental factors that modulate directed connections between regions, using dynamic causal modeling (a tool for measuring effective connectivity). The entropy of spontaneous brain activity is best assessed with MEG and EEG, but efforts to compute entropy on the spontaneous BOLD signal, as well as the entropy rate (Lempel-Ziv complexity) and indices of criticality, have also been attempted (see <xref ref-type="supplementary-material" rid="SD1">Section S1.2</xref> for a full list of citations). While studies on BOLD activation and functional connectivity are common for most subject areas within cognitive neuroscience, entropy is a rather unique feature of the psychedelic neuroimaging literature. The studies on entropy were motivated by Robin Carhart-Harris’ influential <italic>Entropic Brain Hypothesis</italic> (EBH) (<xref ref-type="bibr" rid="R25">Carhart-Harris et al., 2014</xref>; <xref ref-type="bibr" rid="R20">Carhart-Harris, 2018</xref>), which states that psychedelics alter consciousness by elevating the entropy of spontaneous brain activity across time.</p><p id="P11">We performed a quantitative meta-analysis of the pairwise functional connectivity data using a novel algorithm. We initially attempted to conduct a quantitative meta-analysis of the BOLD activation data with the GingerALE method, which examines common clusters of BOLD activity across studies. However, we found that the data was too heterogeneous for the results to be valid. From the outset, we decided to provide a qualitative discussion of the studies on entropy, due to the wide range of methods in that section of the literature.</p></sec><sec id="S4"><label>Section 1.3</label><title>Pharmacology</title><p id="P12">Chemically, psychedelics fall into three categories: tryptamines (e.g. DMT, psilocybin, ayahuasca), ergolines (e.g. LSD), and phenethylamines (e.g. mescaline, 2C-B) (<xref ref-type="bibr" rid="R93">Nichols, 2018</xref>). The molecular structure of tryptamine psychedelics strongly resembles that of serotonin; in fact, serotonin is itself a tryptamine, as both are synthesised from the same amino acid, tryptophan (<xref ref-type="bibr" rid="R16">Brandt et al., 2004</xref>). Ergolines are rigid and more complex analogues of tryptamines (<xref ref-type="bibr" rid="R91">Nichols, 2004</xref>), whereas the chemical backbone of phenethylamines is not the same as that of tryptamines; it is instead constituted from the amino acid phenylalanine (<xref ref-type="bibr" rid="R45">Fantegrossi et al., 2008</xref>).</p><p id="P13">Despite their chemical differences, both tryptamines and phenethylamines – indeed, all classic psychedelics – activate serotonin receptors. Phenethylamines are very selective for the serotonin-2 (5-HT<sub>2</sub>) receptor subtype, including 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub>, whereas tryptamines exhibit a more “promiscuous” binding profile, as they also have affinity for the 5-HT<sub>1</sub> receptor subtype (<xref ref-type="bibr" rid="R6">Araújo et al., 2015</xref>). In spite of the broad range of serotonin receptors that psychedelics, especially tryptamines, bind to, their interaction with the 5-HT<sub>2A</sub> receptor is their primary mechanism of action (<xref ref-type="bibr" rid="R53">González-Maeso et al., 2007</xref>; <xref ref-type="bibr" rid="R78">López-Giménez &amp; González-Maeso, 2018</xref>). Multiple studies have demonstrated that blocking the 5-HT<sub>2A</sub> receptor with antagonists such as ketanserin eliminates their subjective effects (<xref ref-type="bibr" rid="R104">Preller et al., 2017</xref>; <xref ref-type="bibr" rid="R107">Quednow et al., 2012</xref>; <xref ref-type="bibr" rid="R144">Vollenweider et al., 1998</xref>). 5-HT<sub>2A</sub> is expressed postsynaptically in the apical dendrites of layer V pyramidal neurons (<xref ref-type="bibr" rid="R9">Barrett et al., 2020</xref>; <xref ref-type="bibr" rid="R23">R. L. Carhart-Harris et al., 2016</xref>; <xref ref-type="bibr" rid="R28">Dai et al., 2023</xref>; <xref ref-type="bibr" rid="R50">Girn et al., 2022</xref>; <xref ref-type="bibr" rid="R75">Lebedev et al., 2015</xref>; <xref ref-type="bibr" rid="R82">Madsen et al., 2021</xref>; <xref ref-type="bibr" rid="R87">Müller, Dolder, et al., 2018</xref>; <xref ref-type="bibr" rid="R87">Müller, Liechti, et al., 2018</xref>; <xref ref-type="bibr" rid="R115">Roseman et al., 2014</xref>)(<xref ref-type="bibr" rid="R4">Aleksandrova &amp; Phillips, 2021</xref>; <xref ref-type="bibr" rid="R58">Hamada et al., 1998</xref>; <xref ref-type="bibr" rid="R67">Jakab &amp; Goldman-Rakic, 1998</xref>), which are the primary excitatory neurons in mammalian cortex (<xref ref-type="bibr" rid="R121">Spruston, 2008</xref>). Binding to 5-HT<sub>2A</sub> amplifies the firing rate of pyramidal neurons (<xref ref-type="bibr" rid="R9">Barrett et al., 2020</xref>; <xref ref-type="bibr" rid="R28">Dai et al., 2023</xref>; <xref ref-type="bibr" rid="R50">Girn et al., 2022</xref>; <xref ref-type="bibr" rid="R75">Lebedev et al., 2015</xref>; <xref ref-type="bibr" rid="R82">Madsen et al., 2021</xref>; <xref ref-type="bibr" rid="R87">Müller, Dolder, et al., 2018</xref>; <xref ref-type="bibr" rid="R87">Müller, Liechti, et al., 2018</xref>; <xref ref-type="bibr" rid="R115">Roseman et al., 2014</xref>)(<xref ref-type="bibr" rid="R9">Barrett et al., 2020</xref>; <xref ref-type="bibr" rid="R28">Dai et al., 2023</xref>; <xref ref-type="bibr" rid="R50">Girn et al., 2022</xref>; <xref ref-type="bibr" rid="R75">Lebedev et al., 2015</xref>; <xref ref-type="bibr" rid="R82">Madsen et al., 2021</xref>; <xref ref-type="bibr" rid="R87">Müller, Dolder, et al., 2018</xref>; <xref ref-type="bibr" rid="R115">Roseman et al., 2014</xref>)(<xref ref-type="bibr" rid="R9">Barrett et al., 2020</xref>; <xref ref-type="bibr" rid="R23">R. L. Carhart-Harris et al., 2016</xref>; <xref ref-type="bibr" rid="R28">Dai et al., 2023</xref>; <xref ref-type="bibr" rid="R50">Girn et al., 2022</xref>; <xref ref-type="bibr" rid="R75">Lebedev et al., 2015</xref>; <xref ref-type="bibr" rid="R82">Madsen et al., 2021</xref>; <xref ref-type="bibr" rid="R87">Müller, Dolder, et al., 2018</xref>; <xref ref-type="bibr" rid="R115">Roseman et al., 2014</xref>)(<xref ref-type="bibr" rid="R9">Barrett et al., 2020</xref>; <xref ref-type="bibr" rid="R28">Dai et al., 2023</xref>; <xref ref-type="bibr" rid="R50">Girn et al., 2022</xref>; <xref ref-type="bibr" rid="R75">Lebedev et al., 2015</xref>; <xref ref-type="bibr" rid="R87">Müller, Dolder, et al., 2018</xref>)(<xref ref-type="bibr" rid="R105">Puig et al., 2003</xref>) and upregulates the release of glutamate by increasing the amplitude and frequency of excitatory postsynaptic potentials (<xref ref-type="bibr" rid="R2">Aghajanian &amp; Marek, 1997</xref>, <xref ref-type="bibr" rid="R3">1999</xref>). 5-HT<sub>2A</sub> expression is profuse in human cortex, with one study finding highest expression in the posterior cing(<xref ref-type="bibr" rid="R9">Barrett et al., 2020</xref>; <xref ref-type="bibr" rid="R23">R. L. Carhart-Harris et al., 2016</xref>; <xref ref-type="bibr" rid="R28">Dai et al., 2023</xref>; <xref ref-type="bibr" rid="R50">Girn et al., 2022</xref>; <xref ref-type="bibr" rid="R75">Lebedev et al., 2015</xref>; <xref ref-type="bibr" rid="R82">Madsen et al., 2021</xref>; <xref ref-type="bibr" rid="R87">Müller, Dolder, et al., 2018</xref>; <xref ref-type="bibr" rid="R115">Roseman et al., 2014</xref>)ulate cortex and V1 (<xref ref-type="bibr" rid="R9">Barrett et al., 2020</xref>; <xref ref-type="bibr" rid="R23">R. L. Carhart-Harris et al., 2016</xref>; <xref ref-type="bibr" rid="R28">Dai et al., 2023</xref>; <xref ref-type="bibr" rid="R50">Girn et al., 2022</xref>; <xref ref-type="bibr" rid="R75">Lebedev et al., 2015</xref>; <xref ref-type="bibr" rid="R82">Madsen et al., 2021</xref>; <xref ref-type="bibr" rid="R87">Müller, Liechti, et al., 2018</xref>; <xref ref-type="bibr" rid="R115">Roseman et al., 2014</xref>)(<xref ref-type="bibr" rid="R9">Barrett et al., 2020</xref>; <xref ref-type="bibr" rid="R23">R. L. Carhart-Harris et al., 2016</xref>; <xref ref-type="bibr" rid="R28">Dai et al., 2023</xref>; <xref ref-type="bibr" rid="R50">Girn et al., 2022</xref>; <xref ref-type="bibr" rid="R75">Lebedev et al., 2015</xref>; <xref ref-type="bibr" rid="R82">Madsen et al., 2021</xref>; <xref ref-type="bibr" rid="R87">Müller, Dolder, et al., 2018</xref>; <xref ref-type="bibr" rid="R87">Müller, Liechti, et al., 2018</xref>; <xref ref-type="bibr" rid="R115">Roseman et al., 2014</xref>)(<xref ref-type="bibr" rid="R12">Beliveau et al., 2017</xref>). In both humans and monkeys, 86-100% of glutamatergic cells in layers II-V of cortex express mRNA encoding 5-HT<sub>2A</sub> receptors (<xref ref-type="bibr" rid="R33">de Almeida &amp; Mengod, 2007</xref>). 5-HT<sub>2A</sub> has also been identified in many subcortical regions (<xref ref-type="bibr" rid="R92">Nichols, 2016</xref>), though human PET imaging implies lower expression than in the cortex (<xref ref-type="bibr" rid="R12">Beliveau et al., 2017</xref>).</p><p id="P14">Although the consciousness-altering effects of psychedelics do primarily arise from their action at the 5-HT<sub>2A</sub> receptor, we stress that different psychedelics display different binding profiles. For instance, unlike DMT and psilocybin, LSD has moderate affinity for dopamine receptors (<xref ref-type="bibr" rid="R35">de Vos et al., 2021</xref>). Differences in binding affinities could partially account for the distinctive phenomenology of each psychedelic. There is also some evidence that the 5-HT<sub>1A</sub> and 5-HT<sub>2C</sub> receptors may mediate the effects of psychedelics (<xref ref-type="bibr" rid="R18">Canal &amp; Murnane, 2017</xref>; <xref ref-type="bibr" rid="R101">Pokorny et al., 2016</xref>).</p><p id="P15">However, binding affinity paints an incomplete picture of the pharmacology of psychedelics. Another key aspect is their functional activity at receptors. Serotonin and dopamine receptors are G protein-coupled receptors (GPCRs) (<xref ref-type="bibr" rid="R57">Gurevich et al., 2016</xref>; <xref ref-type="bibr" rid="R119">Shah et al., 2020</xref>), which perform essential roles in neurophysiological processes like smell, taste, light perception, and more (<xref ref-type="bibr" rid="R34">de Oliveira et al., 2019</xref>). GPCRs regulate these processes through G protein signaling pathways, which are initiated when agonists bind to GPCRs and activate G proteins (<xref ref-type="bibr" rid="R136">Tuteja, 2009</xref>). Different families of G proteins are selective for particular signaling pathways (<xref ref-type="bibr" rid="R51">Giulietti et al., 2014</xref>). In a phenomenon known as biased agonism, agonists can induce certain conformations in GPCRs, which then selectively activates certain pathways and not others (<xref ref-type="bibr" rid="R5">Andresen, 2011</xref>). 5-HT<sub>2</sub> receptors couple preferentially to a family of G proteins known as Gα<sub>q/11</sub>, which activates the enzyme phospholipase C (PLC). This enzyme then catalyses the synthesis of the secondary messenger inositol triphosphate (IP<sub>3</sub>, a species of inositol phosphate [IP]), which subsequently leads to the release or “mobilisation” of calcium from the endoplasmic reticulum (<xref ref-type="bibr" rid="R78">López-Giménez &amp; González-Maeso, 2018</xref>). Psychedelics are also known to recruit β-arrestin proteins (<xref ref-type="bibr" rid="R102">Pottie, Cannaert, et al., 2020</xref>; <xref ref-type="bibr" rid="R102">Pottie, Dedecker, et al., 2020</xref>; <xref ref-type="bibr" rid="R112">Rodriguiz et al., 2021</xref>; <xref ref-type="bibr" rid="R117">Schmitz et al., 2022</xref>). These proteins block the interaction between G proteins and the GPCR and remove the GPCR from the cell membrane, while also coupling GPCRs to signaling proteins without activating G proteins; thus, β-arrestin promotes alternative signaling pathways (<xref ref-type="bibr" rid="R14">Bohn &amp; Schmid, 2010</xref>). Functional GPCR assays on psychedelics have tended to focus on the three aspects of GPCR signaling described above: (1) IP formation, (2) calcium mobilisation, and (3) β-arrestin (specifically β-arrestin2) recruitment.</p><p id="P16">We performed a meta-analysis of the selective affinity of DMT, LSD, and psilocin for the 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, and D<sub>2</sub> receptors, relative to the 5-HT<sub>1A</sub> receptor. Additionally, we conducted a meta-analysis of their functional activity at the 5-HT<sub>2A</sub> receptor, as measured by the three aforementioned assays.</p></sec></sec><sec id="S5" sec-type="results"><label>Section 2</label><title>Results</title><p id="P17">We present the results of our meta-analysis of the phenomenology, neuroimaging, and pharmacology of three classical psychedelics: DMT, LSD, and psilocybin. At each level, we measured the alignment between the corresponding results and the Yeo networks, which facilitated comparisons between the three hierarchical levels.</p><sec id="S6"><label>Section 2.1</label><title>Phenomenology</title><p id="P18">We performed a meta-analysis on the 5D- and 11D-ASC scores of DMT, LSD, and psilocybin. Our literature search identified <italic>n</italic> = 44 phenomenology studies that met the inclusion criteria, including 5 studies on DMT (5D-ASC: <italic>n</italic> = 3; 11D-ASC: <italic>n</italic> = 3), 14 studies on LSD (5D-ASC: <italic>n</italic> = 9; 11D-ASC: <italic>n</italic> = 12), and 25 studies on psilocybin (5D-ASC: <italic>n</italic> = 12; 11D-ASC: <italic>n</italic> = 17). The eleven dimensions of the 11D-ASC are subscales of three dimensions in the 5D-ASC: oceanic boundlessness (OB), anxious ego dissolution (AED), and visionary restructuralisation (VR). Nevertheless, the 11D-ASC questionnaire contains fewer items than the 5D-ASC questionnaire, so 5D-ASC data cannot be directly compared to 11D-ASC data. Hence, we ran separate meta-analyses for the 5D-ASC and 11D-ASC data. In order to account for the measurement of multiple subjective dimensions, sometimes with more than one dose or drug, in individual studies, we performed a multilevel random-effects meta-analysis (Assink &amp; Wibbelink, 2016; Harrer et al., 2021).</p><p id="P19">DMT was administered intravenously (IV) in the phenomenological studies, whereas LSD and psilocybin were administered orally (we excluded phenomenological studies that used IV LSD and psilocybin). IV administration yields different pharmacokinetics, which are known to influence the subjective experience of the drug (<xref ref-type="bibr" rid="R79">Luan et al., 2023</xref>; <xref ref-type="bibr" rid="R141">Vogt et al., 2023</xref>). Therefore, while we conducted meta-analyses of all three drugs, we only examined significant between-drug differences for ASC ratings of LSD and psilocybin. Additionally, we only compared similar doses of LSD and psilocybin. We assumed 20 mg psilocybin is equivalent to 0.01 mg LSD (<xref ref-type="bibr" rid="R77">Ley et al., 2023</xref>), and we defined low, medium, and high doses based on the literature (<xref ref-type="bibr" rid="R19">Carbonaro et al., 2018</xref>; <xref ref-type="bibr" rid="R60">Hasler et al., 2004</xref>; <xref ref-type="bibr" rid="R142">Vollenweider et al., 2007</xref>).</p><p id="P20">Pooled 5D-ASC scores for DMT, LSD, and psilocybin are shown in <xref ref-type="fig" rid="F1">Figure 1</xref> (numerical data are given in <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Between-drug differences for LSD and psilocybin are displayed in the left column of <xref ref-type="fig" rid="F1">Figure 1a-c</xref>, and within-drug differences are displayed in the right column. At medium doses (LSD: 0.075-0.109 mg, psilocybin: 15-21 mg), 5D-ASC scores were significantly greater for LSD than psilocybin in the OB dimension (<italic>p</italic> = 0.0283), which corresponds to feelings of interconnectedness, and the VR dimension (<italic>p</italic> = 0.0468), which measures the quality and intensity of visual hallucinations. We also observed a significant difference between LSD and psilocybin in the VR dimension (<italic>p</italic> = 0.0417) at high doses (LSD: ≥0.010 mg, psilocybin: ≥22 mg). There were no significant differences at low doses (LSD: 0.050-0.074 mg, psilocybin: 8-14 mg).</p><p id="P21">Within-drug differences between the five subjective dimensions were quite similar. A clear separation can be seen between two groups of subjective categories: (1) OB, VR, RV, and (2) AA and AED. At medium doses, VR and OB scores were significantly higher than both AED and AA scores for both LSD and psilocybin. Intriguingly, RV scored higher than all other dimensions at low doses of psilocybin, but this comparison was not significant. For DMT, there were no significant differences between dimensions at high doses (≥16 mg bolus injection, followed by continuous infusion of 1 mg/min), but for low doses (10-15 mg bolus + 0.6-0.99 mg/min continuous infusion), AED ranked significantly lower than both OB and VR. (Note that only one study measured AA and RV scores for DMT (<xref ref-type="bibr" rid="R141">Vogt et al., 2023</xref>), so we did not perform a meta-analysis on these dimensions for DMT.)</p><p id="P22">The results of the 11D-ASC meta-analysis were not very consistent with those of the 5D-ASC meta-analysis (<xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>; <xref ref-type="supplementary-material" rid="SD1">Table S2</xref>). Note that we could not include DMT in the 11D-ASC meta-analysis because two of the three studies on DMT did not report standard errors, which are necessary for pooling the subjective data. At high doses, there were no significant differences between LSD and psilocybin in any of the dimensions, and standard errors were very large for psilocybin in some dimensions, particularly in some OB and VR subscales. At medium doses, where standard errors tended to be lower, we observed that two of the OB subscales (experience of unity and insightfulness), one of the AED subscales (impaired control and cognition), and three of the VR subscales (complex imagery, audio-visual synaesthesia, and changed meaning of percepts) ranked significantly higher for LSD than psilocybin. In line with the 5D-ASC results, we did not find any significant differences between LSD and psilocybin at low doses. However, unlike the 5D-ASC analysis, the 11D-ASC analysis showed that psilocybin rated higher than LSD in most of the dimensions; that being said, standard errors were very high for both LSD and psilocybin, so our estimates are not reliable. For medium doses, within-drug comparisons for the 11D-ASC analysis generally aligned with those of the 5D-ASC analysis.</p><p id="P23">We did not find any significant relationship between the pooled 5D-ASC scores and three methodological covariates that were defined <italic>a priori</italic>: prior psychedelic use, the time that the questionnaire was administered relative to the administration of the drug, and the presence or absence of a task in the experiment. Residual heterogeneity did not have a significant influence on estimates of pooled 5D- or 11D-ASC scores (<italic>p</italic> &lt; 0.0001 in both cases). Unfortunately, we were unable to obtain reliable estimates of heterogeneity specifically attributable to within-study and between-study differences.</p><p id="P24">In order to directly compare the phenomenology of psychedelics to their neuroimaging and pharmacological profiles (<xref ref-type="sec" rid="S7">Section 2.2</xref> and <xref ref-type="sec" rid="S8">Section 2.3</xref>), we sought to determine the “phenomenology profiles” of DMT, LSD, and psilocybin based on the neural correlates of their subjective effects. We performed a separate literature search of studies that measured correlations between ASC ratings and fMRI activity. We determined the Yeo network that contained each brain region that exhibited a significant correlation. The phenomenology profiles were defined by a weighted combination of the mean correlations between each ASC scale and each Yeo network, in which the weights were the pooled ASC ratings of each psychedelic for the corresponding scale.</p><p id="P25">Because there were few significant differences in the pooled ASC scores, the phenomenology profiles of the psychedelics look very similar (<xref ref-type="fig" rid="F2">Figure 2</xref>). However, these profiles may not reflect the true neural correlates of the subjective effects of psychedelics. Many studies performed correlations between ASC ratings and brain regions that were active only in specific tasks, but the tasks varied strongly in the literature.</p><p id="P26">The ventral attention network (VAN) appears to be more strongly associated with the subjective effects than any of the other Yeo networks, but this result may be an artifact of one study’s decision to correlate the ASC ratings with a seed in the VAN. There need to be more studies that link whole-brain fMRI activity to ASC ratings before we can estimate the phenomenology profiles with confidence.</p><p id="P27">Finally, we also aimed to relate the phenomenology of different psychedelics by qualitatively synthesising the findings of papers that directly compared the subjective experiences of DMT/ayahuasca, LSD, and psilocybin. <xref ref-type="supplementary-material" rid="SD1">Section S3</xref> contains a comprehensive summary of their major aims, analysis approaches and findings.</p></sec><sec id="S7"><label>Section 2.2</label><title>Neuroimaging</title><p id="P28">As stated above, the fMRI studies on psychedelics measure three different characteristics of brain activity: BOLD activation, entropy, and connectivity. We identified <italic>n</italic> = 17 studies on BOLD activation, including <italic>n</italic> = 3 studies on ayahuasca or DMT, <italic>n</italic> = 7 studies on LSD, and <italic>n</italic> = 4 studies on psilocybin. Initially, we used the GingerALE method to determine common clusters of BOLD activation across studies. We observed that psilocybin was associated with a cluster of activity in visual cortices, whereas LSD tended to affect more frontal areas. However, three of the four studies on psilocybin displayed visual stimuli to participants. Therefore, our results were likely confounded by the tasks that were used in the literature. We chose not to report the results of our GingerALE analysis because they are likely misleading.</p><p id="P29">The <italic>n</italic> = 12 fMRI studies on entropy and criticality in the psychedelic literature are very heterogeneous, employing a wide variety of measures on dissimilar variables of interest. A quantitative meta-analysis was extremely challenging, so we opted instead to perform a qualitative review of this literature, which is reported in <xref ref-type="supplementary-material" rid="SD1">Section S4</xref>.</p><p id="P30">The studies on connectivity were the only segment of the fMRI literature for which we determined that we could conduct a valid meta-analysis. These studies tended to use the same resting-state experimental procedure, and many of them employed similar methods for measuring connectivity. However, one major obstacle was the variety of parcellations in the literature. Since each study defined regions of interest (ROIs) in a different way, it was not possible to simply perform a weighted average of connectivity values across studies. (This weighted average method is essentially the core technique of the phenomenology and pharmacology meta-analyses.) An alternative approach is to “re-reference” the data to a coarse-grained parcellation: the Yeo networks, of which there are only seven in the brain (<xref ref-type="bibr" rid="R131">Thomas Yeo et al., 2011</xref>). That is, for every pair of functionally connected ROIs in the literature, we determine the corresponding Yeo networks that contain them. If the connection is positive (it increases under psychedelics), then the aggregate FC between those Yeo networks is incremented; otherwise, it is decremented. Our method for weighting each connection in the literature is described in <xref ref-type="supplementary-material" rid="SD1">Section S2.2.2</xref>. We determined significance by repeatedly applying our method to an independent resting-state fMRI dataset of sober individuals, which resulted in a null distribution (<xref ref-type="bibr" rid="R140">Van Essen et al., 2013</xref>).</p><p id="P31">This method is capable of synthesising studies on pairwise FC, such as seed-to-seed, seed-to-voxel, and within- and between-network FC analyses using independent components analysis (see <xref ref-type="supplementary-material" rid="SD1">Table S4</xref> for a full description of the inputs). The algorithm cannot accommodate global, structural metrics of connectivity such as global brain connectivity (GBC) or graph-theoretic modularity. Additionally, the algorithm does not capture any information about the direction of connectivity between regions; therefore, we did not incorporate studies of effective connectivity or directed FC. (However, the vast majority of FC studies measured undirected FC.)</p><p id="P32">Many FC studies are secondary analyses of the same primary dataset. For instance, the primary FC data from <xref ref-type="bibr" rid="R23">Carhart-Harris et al. (2016)</xref> was re-analysed at least seven times with different methods in subsequent studies. To mitigate bias, we only inputted the most informative analysis of each unique dataset into the meta-analysis algorithm, such that each dataset was only represented once in the meta-analysis. Our method for selecting the most informative analysis is described in <xref ref-type="supplementary-material" rid="SD1">Section S2.2.2</xref>.</p><p id="P33">Based on these criteria and others, we ultimately identified <italic>n</italic> = 12 studies on connectivity that were eligible for our meta-analysis, including <italic>n</italic> = 3 studies on ayahuasca or DMT, <italic>n</italic> = 3 studies on LSD, and <italic>n</italic> = 6 studies on psilcoybin. (There are 22 other studies on connectivity that we qualitatively review in <xref ref-type="supplementary-material" rid="SD1">Section S5</xref>.) Our estimates of aggregate FC between Yeo networks, across all psychedelics, are shown in <xref ref-type="fig" rid="F3">Figure 3</xref>. Psychedelics significantly strengthened between-network connectivity. Within-network connectivity decreased in all networks except for the frontoparietal network (FPN). However, the increase in the FPN was significant, whereas all the decreases were not, despite the fact that the reduction in within-network FC for the visual network was disproportionately greater than for all other networks.</p><p id="P34">In addition to aggregating FC across all psychedelics, we performed our analysis separately on each individual psychedelic (<xref ref-type="supplementary-material" rid="SD1">Figure S4</xref>). All three of the psychedelics lowered FC in the visual network and default mode network (DMN) and generally elevated between-network FC. Intriguingly, ayahuasca/DMT disproportionately augmented FC between two “transmodal” or associative networks (FPN and DMN) &amp; the two “unimodal” or sensory networks (visual and somamotor network [SMN]), while strongly reducing FC within and between the two sensory networks. LSD dramatically increased FC between the visual network and all other networks, yet sharply decreased FC within the visual network. Summing across the rows of each aggregate FC matrix, we find that DMT and psilocybin tend to affect the FC of the DMN the most, whereas LSD displays a more uniform profile of changes in FC across the Yeo networks (<xref ref-type="fig" rid="F6">Figure 6</xref>).</p><p id="P35">Finally, there was no significant association between our results and any of the methodological covariates in the literature that we identified a priori: the width of the Gaussian kernel used to smooth the data, the use of FSL or SPM, the technique used to regress out white matter, and the presence or absence of scrubbing to correct head motion.</p></sec><sec id="S8"><label>Section 2.3</label><title>Pharmacology</title><p id="P36">We performed two separate meta-analyses on the pharmacology of psychedelics. The first assessed the selective affinity of DMT, LSD, and psilocin for the 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, and D<sub>2</sub> receptors, relative to 5-HT<sub>1A</sub>. The second examined the relative functional activity of the psychedelics at the 5-HT<sub>2A</sub> receptor, as captured in three different assays of GPCR signaling.</p><sec id="S9"><label>Section 2.3.1</label><title>Affinity</title><p id="P37">We first present our meta-analysis of the selective affinity data. Selectivity is defined as the ratio between the <italic>K</italic><sub>i</sub> of each psychedelic for a receptor of interest, relative to a reference receptor. <italic>K</italic><sub>i</sub> refers to the inhibition constant, which reflects the concentration of a drug that is needed to inhibit the binding of another ligand, for instance a radioactively-labeled ligand (radioligand), to the receptor of interest; it is inversely related to binding affinity (<xref ref-type="bibr" rid="R127">Sykes et al., 2019</xref>). We chose 5-HT<sub>1A</sub> to be the reference receptor. We decided to analyse selectivity rather than absolute <italic>K</italic><sub>i</sub> because the latter is biased by the potency of the drug. Since LSD is much more potent than DMT and psilocin (<xref ref-type="bibr" rid="R111">Rickli et al., 2016</xref>), the meta-analysis would have simply revealed that LSD has higher affinity for all receptors if we were to examine the absolute <italic>K</italic><sub>i</sub> instead.</p><p id="P38">Our literature search identified <italic>n</italic> = 14 studies on selectivity, including <italic>n</italic> = 6 studies on DMT, <italic>n</italic> = 9 studies on LSD, and <italic>n</italic> = 5 studies on psilocin. We performed a random-effects meta-analysis with the drugs as covariates. Pooled selectivity values are displayed in <xref ref-type="fig" rid="F5">Figure 5a</xref> (numerical data are given in <xref ref-type="supplementary-material" rid="SD1">Table S8</xref>). We found no significant between-drug differences in selectivity for any of the receptors – 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, and D<sub>2</sub> – relative to the 5-HT<sub>1A</sub> receptor. Standard errors were very large for all of the pooled selectivity values, and heterogeneity was very high for the 5-HT<sub>2A</sub> selectivity data (<italic>I</italic><sup>2</sup> = 93.69%) and for the 5-HT<sub>2C</sub> selectivity data (<italic>I</italic><sup>2</sup> = 99.14%). Nevertheless, it is clear that all drugs display less selectivity for D<sub>2</sub> than they do for 5-HT<sub>2C</sub> and 5-HT<sub>2A</sub>. Each individual drug is more selective for 5-HT<sub>2A</sub> than 5-HT<sub>1A</sub>. DMT and psilocin are about as equally selective for 5-HT<sub>2C</sub> as they are for 5-HT<sub>1A</sub>, but LSD is much less selective for 5-HT<sub>2C</sub> than for 5-HT<sub>1A</sub>.</p><p id="P39">We constructed another random-effects model in which both the drug and the radioligand for the receptor of interest were included as covariates; we refer to this as the “full” model and the previous one as the “reduced” model. For 5-HT<sub>2A</sub>, the use of the radioligands [<sup>3</sup>H]-ketanserin (<italic>p</italic> = 0.0141) and [<sup>3</sup>H]-spiperone (<italic>p</italic> = 0.0271) significantly influenced the pooled selectivity estimates. Use of [<sup>3</sup>H]-mesulgerine (<italic>p</italic> = 0.0292), but not [3H]-ketanserin (<italic>p</italic> = 0.0872), significantly affected our estimates of selectivity for 5-HT<sub>2C</sub>. According to the corrected Akaike’s information criterion, the full model performed significantly better than the reduced model for 5-HT<sub>2A</sub> selectivity (p &lt; 0.0001), whereas the reverse was true for 5-HT<sub>2C</sub> selectivity (<italic>p</italic> = 0.0024).</p><p id="P40">To relate the selective affinities to the neuroimaging and phenomenology of psychedelics, we first determined the expression of the 5-HT<sub>2A</sub> and D<sub>2</sub> receptors in the Yeo networks, based on an atlas of PET maps (<xref ref-type="bibr" rid="R59">Hansen et al., 2022</xref>) (unfortunately, this did not include maps of the 5-HT<sub>2C</sub> receptor). Then, we defined the “pharmacology profile” as the weighted combination of the expression patterns, in which the weights were the selectivity of each psychedelic for the corresponding receptor (<xref ref-type="fig" rid="F6">Figure 6</xref>). The PET atlas indicates that 5-HT<sub>2A</sub> receptor density is around two orders of magnitude higher than that of D<sub>2</sub> receptor density, so the pharmacology profile predominantly reflects selectivity for 5-HT<sub>2A</sub>. Because psilocin’s selectivity for 5-HT<sub>2A</sub> is greater than that of LSD and DMT, psilocin has the “largest” pharmacology profile. 5-HT<sub>2A</sub> is expressed more in transmodal networks than the visual network; thus, selectivity for 5-HT<sub>2A</sub> may affect brain activity the most in these networks.</p></sec><sec id="S10"><label>Section 2.3.2</label><title>Functional activity</title><p id="P41">Binding affinity is only one facet of the pharmacology of psychedelics. Another key aspect is their functional activity: the responses that they elicit in receptors after binding to them. While there are many ways to measure functional activity, we focused on GPCR signaling through three different pathways: (1) IP formation, (2) calcium mobilisation, and (3) β-arrestin2 recruitment. We limited our analysis to functional activity at specifically the 5-HT<sub>2A</sub> receptor, as there was simply much more data about this receptor in humans.</p><p id="P42">When a drug is a partial, rather than full, agonist at a receptor, estimates of functional activity are affected in a nonlinear manner by the sensitivity of the assay (<xref ref-type="bibr" rid="R69">Kenakin, 2017</xref>). The sensitivity of an assay can increase or decrease, for instance, based on whether the cells in the assay overexpress the receptor of interest or express it at endogenous levels. One solution is to compare the relative activity, defined as Δlog(<italic>E</italic><sub>max</sub>/EC<sub>50</sub>) (<xref ref-type="bibr" rid="R70">Kenakin et al., 2011</xref>). E<sub>max</sub> is the maximal response elicited by the drug of interest, relative to a reference ligand, and EC<sub>50</sub> is the concentration of drug that is needed to bring about 50% of the maximal response. Δ refers to the difference between the activity of the drug of interest and a reference ligand. Because activity is quantified relative to the reference ligand, this measure essentially cancels out differences in assay sensitivity (<xref ref-type="bibr" rid="R69">Kenakin, 2017</xref>). Thus, there is no need to include differences between assays, such as the cell line, as covariates in the meta-analysis.</p><p id="P43">We found <italic>n</italic> = 18 relevant studies on functional activity, including <italic>n</italic> = 6 studies on DMT, <italic>n</italic> = 13 studies on LSD, and <italic>n</italic> = 6 studies on psilocin. We performed a random-effects meta-analysis, with the drugs as covariates. For the IP formation and calcium mobilisation assays, the reference ligand was serotonin; for the β-arrestin2 recruitment assays, the reference ligand was chosen to be mescaline, as this was the only reference ligand used in experiments on all three psychedelics. The pooled relative activity values indicate that LSD induces significantly more IP formation than DMT (<italic>p</italic> &lt; 0.0001) and psilocin (<italic>p</italic> = 0.0002) (<xref ref-type="fig" rid="F5">Figure 5b</xref>). Additionally, DMT elicits significantly more IP formation than psilocin (<italic>p</italic> = 0.0203). There were no significant between-drug differences for the other two pathways. Heterogeneity was very high for all three pathways (IP formation: <italic>I</italic><sup>2</sup> = 95.35%, calcium mobilisation: <italic>I</italic><sup>2</sup> = 92.66%, β-arrestin2 recruitment: <italic>I</italic><sup>2</sup> = 91.05%).</p></sec></sec></sec><sec id="S11" sec-type="discussion"><label>Section 3</label><title>Discussion</title><p id="P44">Here we examine the effects of psychedelics at three levels: 1) subjective experience (phenomenology), 2) functional connectivity (neuroimaging), and 3) the interaction of psychedelics with serotonin and dopamine receptors (pharmacology). At each level, we performed a quantitative meta-analysis and computed the alignment between the results and the seven resting-state Yeo networks. The latter network analysis enabled us to directly compare the effects of three psychedelics – ayahuasca/DMT, LSD, and psilocybin – within and between levels. It is worth noting that, while we refer to these three levels of description as a “hierarchy,” we do not mean to imply a simple “vertical” causal structure, in which the pharmacology determines the neuroimaging, which in turn decides the phenomenology. Instead, there is a highly complex network of causal relationships between these three levels, with many feedback loops (<xref ref-type="bibr" rid="R13">Block, 1991</xref>; <xref ref-type="bibr" rid="R72">Kringelbach et al., 2020</xref>).</p><sec id="S12"><label>Section 3.1</label><title>Unifying the levels of the hierarchy</title><p id="P45">For the phenomenology literature, we conducted a meta-analysis of both the 5-dimensional and 11-dimensional versions of the Altered States of Consciousness (ASC) scale, a common questionnaire for measuring changes in subjective experience on psychedelics. At both medium and high doses, LSD ranked significantly higher than psilocybin in “visionary restructuralisation,” a dimension capturing the quality and intensity of visual hallucinations. The VAN appears to be correlated with the phenomenology of all three psychedelics, but this result may be spurious due to the small number of studies that measured correlations between ASC ratings and fMRI activity. Nevertheless, there are reasons to think that the VAN may be uniquely implicated in the phenomenology of psychedelics. The VAN is responsible for orienting attention toward surprising objects or events (<xref ref-type="bibr" rid="R146">Vossel et al., 2014</xref>), and it is engaged during mismatch negativity (MMN), an event-related potential that is triggered when an unexpected stimulus is shown (<xref ref-type="bibr" rid="R76">Lee et al., 2017</xref>). Psychedelics diminish the MMN response while enhancing the neural response to familiar stimuli (<xref ref-type="bibr" rid="R42">Duerler et al., 2021</xref>; <xref ref-type="bibr" rid="R133">Timmermann et al., 2018</xref>), perhaps because these drugs engender profound feelings of childlike awe and wonder (<xref ref-type="bibr" rid="R62">Hendricks, 2018</xref>). This heightened predisposition towards subjective experiences of novelty may increase activity in the VAN.</p><p id="P46">The whole-brain neuroimaging data consisted of three subsets of data: BOLD activation, entropy, and FC. We did not report a meta-analysis of the BOLD activation or entropy literature due to the heterogeneity of experimental procedures and analysis methods, respectively; however, we did conduct a qualitative review of the entropy literature (<xref ref-type="supplementary-material" rid="SD1">Section S4</xref>). To perform a meta-analysis on the FC data, we essentially re-parcellated the published data into the Yeo networks and then calculated a weighted sum of the connections between Yeo networks. LSD strongly elevated FC between the visual network and the other networks, whereas ayahuasca/DMT increased FC most between transmodal networks (specifically, the FPN and DMN) and unimodal networks (i.e. SMN and visual).</p><p id="P47">For pharmacology, we conducted two meta-analyses: one of selectivity and another of relative functional activity. There were no significant differences between psychedelics in selectivity for the 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, or D<sub>2</sub> receptors relative to the 5-HT<sub>1A</sub> receptor. Compared to DMT and psilocin, LSD elicited significantly more relative activity in IP formation assays. We did not observe any significant between-drug differences for the calcium mobilisation and β-arrestin2 recruitment assays.</p><p id="P48">Directly comparing the pharmacology, neuroimaging, and phenomenology profiles of psychedelics (<xref ref-type="fig" rid="F7">Figure 7</xref>) reveals a weak one-to-one relationship between the three levels of the hierarchy, which is unsurprising given the highly non-linear, complex, and reciprocal (<xref ref-type="bibr" rid="R72">Kringelbach et al., 2020</xref>) interactions between them. However, the results of the meta-analyses at each level may reveal some insights into the nature of these interactions.</p><p id="P49">On a superficial level, there do appear to be some direct correspondences between the phenomenology, neuroimaging, and pharmacology. Phenomenologically, we only found one significant difference between psychedelics that was consistent across dose levels: LSD induces more visionary restructuralisation than psilocybin does. Neurobiologically, LSD disproportionately enhanced connectivity between the visual network &amp; all other networks, while very strongly reducing connectivity within the visual network. LSD’s effect on FC between other networks was much weaker.</p><p id="P50">The relationship between the pharmacology results and the above findings is more difficult to establish. Our results show that LSD increases IP formation, whereas DMT and psilocin decrease it. IP formation occurs whenever Gα<sub>q</sub> proteins are recruited to initiate cellular signaling. Furthermore, there is evidence that Gα<sub>q</sub> activation is necessary for 5-HT<sub>2A</sub> agonists to bring about hallucinogenic effects. When administered the psychedelic (±)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), mice that lack the gene for Gα<sub>q</sub> proteins do not exhibit behaviours (head twitches) that typically indicate hallucinations (<xref ref-type="bibr" rid="R49">Garcia et al., 2007</xref>). More recently, activation of Gα<sub>q</sub> pathways by 5-HT<sub>2A</sub> agonists has been shown to predict head-twitch behaviour, whereas 5-HT<sub>2A</sub> agonists that are biased for the β-arrestin2 pathway do not induce head twitches (<xref ref-type="bibr" rid="R148">Wallach et al., 2023</xref>). There appears to be a threshold level of Gα<sub>q</sub> activation that must be surpassed in order for a 5-HT<sub>2A</sub> agonist to induce hallucinogenic effects (<xref ref-type="bibr" rid="R148">Wallach et al., 2023</xref>). Intriguingly, the pro-psychotic properties of drugs can be predicted from the extent to which they increase Gα<sub>q</sub> activation (relative to a different G-protein pathway) when these drugs interact with a complex formed between the 5-HT<sub>2A</sub> receptor and a metabotropic glutamate receptor (<xref ref-type="bibr" rid="R47">Fribourg et al., 2011</xref>). In other words, the more that a drug upsets the normal balance of Gα<sub>q</sub> signaling, the more likely it is to engender hallucinations. However, these studies only establish the presence of hallucinations elicited by Gα<sub>q</sub> signaling. They do not indicate whether Gα<sub>q</sub> signaling induces <italic>visual</italic> hallucinations in particular. Thus, we can only speculate that the pharmacology, neuroimaging, and phenomenology literature all convergently indicate that LSD has a uniquely strong effect on visual awareness.</p><p id="P51">There do not appear to be any tools at the moment for relating the pharmacology of drugs to the precise nature of the subjective experiences that they produce. Methods for examining the relationship between neuroimaging and phenomenology are currently limited to correlations and linear regressions (<xref ref-type="bibr" rid="R17">Burt et al., 2021</xref>; <xref ref-type="bibr" rid="R23">R. L. Carhart-Harris et al., 2016</xref>), which do not capture causality. There is a need to develop new techniques for elucidating the causal relationships between phenomenology, neuroimaging, and pharmacology.</p></sec><sec id="S13"><label>Section 3.2</label><title>Relating the results of the meta-analysis to the literature</title><sec id="S14"><label>Section 3.2.1</label><title>Phenomenology</title><p id="P52">We sought to verify the results of our phenomenology meta-analysis by comparing them to the two studies that measured ASC ratings of LSD and psilocybin in the same group of participants. <xref ref-type="bibr" rid="R65">Holze et al. (2022)</xref> gave a medium (15 mg) and a high (30 mg) dose of psilocybin, as well as a medium (0.01 mg) and a high (0.02 mg) dose of LSD, and then compared both 5D- and 11D-ASC scores. It is worth noting that the doses of psilocybin and LSD in this study are not equivalent, since 0.01 mg LSD = 20 mg psilocybin. When comparing 15 mg psilocybin to 0.01 mg LSD, mean 5D-ASC and 11D-ASC scores tended to be higher for LSD than psilocybin. However, the only differences that reached significance were in the OB and VR scales for the 5D-ASC analysis, and in the complex imagery and audio-visual synaesthesia subscales for the 11D-ASC analysis. In our meta-analysis, LSD and psilocybin were significantly different in both OB and VR ratings, and in complex imagery but not audio-visual synaesthesia ratings, at medium doses. <xref ref-type="bibr" rid="R77">Ley et al. (2023)</xref> compared the subjective effects of medium doses of LSD (0.01 mg) and psilocybin (20 mg). Here, the doses are equivalent, unlike in the previous study. The study found no significant differences between LSD and psilocybin in any of the dimensions, both in the 5D and 11D analyses. Therefore, the results of our meta-analysis are not entirely supported by studies that conducted direct comparisons between psychedelics.</p></sec><sec id="S15"><label>Section 3.2.2</label><title>Neuroimaging</title><p id="P53">One major finding in the neuroimaging literature is that psychedelics desegregate and disintegrate brain networks. Segregation is defined as the lack of FC <italic>between</italic> brain regions, while integration denotes FC <italic>within</italic> a network. <xref ref-type="bibr" rid="R23">Carhart-Harris et al. (2016)</xref> found that LSD led to disintegration and desegregation for most RSNs. This finding has been independently confirmed in several other studies (<xref ref-type="bibr" rid="R9">Barrett, Doss, et al., 2020</xref>; <xref ref-type="bibr" rid="R28">Dai et al., 2023</xref>; <xref ref-type="bibr" rid="R50">Girn et al., 2022</xref>; <xref ref-type="bibr" rid="R75">Lebedev et al., 2015</xref>; <xref ref-type="bibr" rid="R82">Madsen et al., 2021</xref>; <xref ref-type="bibr" rid="R87">F. Müller, Dolder, et al., 2018</xref>; <xref ref-type="bibr" rid="R115">Roseman et al., 2014</xref>). In a review of three studies, <xref ref-type="bibr" rid="R87">Müller, Liechti, et al. (2018)</xref> found good convergence in reports of desegregation.</p><p id="P54">Our meta-analysis corroborates the desegregation and disintegration hypothesis. FC significantly increased between all non-identical pairs of brain networks. Within-network FC decreased for all networks except for the FPN. However, all reductions in within-network FC were insignificant. In this meta-analysis, we determined statistical significance by comparing the psychedelic literature to resting-state FC data collected by the Human Connectome Project in sober human participants. However, the HCP data does not reflect the heterogeneity of analysis methods in the psychedelic literature. Whereas we used a whole-brain seed-to-seed FC analysis of the HCP data, many of the studies in the psychedelic literature isolated specific seeds rather than examining the entire brain. Additionally, we applied a single parcellation (DK-80) to the HCP data, whereas multiple parcellations were used in the psychedelic literature. Thus, the insignificant result may reflect inconsistencies between our methods and the literature. Nevertheless, it does raise the intriguing possibility that reductions in within-network FC can sometimes be greater in sober resting-state than on psychedelics.</p><p id="P55">While there is a correlation between desegregation/disintegration and the subjective experience of ego dissolution (<xref ref-type="bibr" rid="R130">Tagliazucchi et al., 2016</xref>), there is no evidence for a <italic>causal</italic> link. There appear to be parallels between the conscious experience of interconnectedness and the “interconnectedness” of the brain on psychedelics, but further research is needed to demonstrate that the connection between the two is more than merely semantic.</p><p id="P56">Another common finding is that psychedelics decrease activity and connectivity within the default mode network (DMN), a region that is generally implicated in self-awareness, self-reflection, and other self-referential cognitive processes (<xref ref-type="bibr" rid="R30">Davey et al., 2016</xref>; <xref ref-type="bibr" rid="R29">Davey &amp; Harrison, 2018</xref>; <xref ref-type="bibr" rid="R84">Molnar-Szakacs &amp; Uddin, 2013</xref>; <xref ref-type="bibr" rid="R85">Moran et al., 2013</xref>). This popular ’meme’ likely has its origin in the first resting-state fMRI study of a psychedelic, where decreased blood flow and BOLD signal were observed in a pattern of regions resembling the DMN (<xref ref-type="bibr" rid="R21">Carhart-Harris et al., 2012</xref>). Eleven years later, evidence continues to indicate that psychedelics potently affect the regularity of population brain activity in DMN regions (<xref ref-type="bibr" rid="R132">Timmermann et al., 2023</xref>). Since a commonly reported experience on psychedelics is the dissolution of the self, a phenomenon known as “ego death” (<xref ref-type="bibr" rid="R86">Moreton et al., 2020</xref>; <xref ref-type="bibr" rid="R94">Nour et al., 2016</xref>; <xref ref-type="bibr" rid="R96">Pahnke, 1969</xref>), it would superficially make sense that psychedelics dysregulate the DMN. Many studies have found significant correlations between subjective ratings of ego dissolution and DMN disintegration (<xref ref-type="bibr" rid="R7">Atasoy et al., 2017</xref>; <xref ref-type="bibr" rid="R9">Barrett, Krimmel, et al., 2020</xref>; <xref ref-type="bibr" rid="R80">Luppi et al., 2021</xref>; <xref ref-type="bibr" rid="R82">Madsen et al., 2021</xref>; <xref ref-type="bibr" rid="R97">Palhano-Fontes et al., 2015</xref>; <xref ref-type="bibr" rid="R98">Pasquini et al., 2020</xref>; <xref ref-type="bibr" rid="R115">Roseman et al., 2014</xref>; <xref ref-type="bibr" rid="R120">Smigielski et al., 2019</xref>; <xref ref-type="bibr" rid="R129">Tagliazucchi et al., 2014</xref>, <xref ref-type="bibr" rid="R130">2016</xref>), though other analyses did not find evidence for a relationship between the two (<xref ref-type="bibr" rid="R75">Lebedev et al., 2015</xref>; <xref ref-type="bibr" rid="R87">F. Müller, Dolder, et al., 2018</xref>).</p><p id="P57">However, claims of “de-activation” or worse, “shutting-off” of the DMN as signatures of psychedelic action are wrong and misleading. Other neuroimaging studies by <xref ref-type="bibr" rid="R21">Carhart-Harris et al. (2012</xref>, <xref ref-type="bibr" rid="R22">2013</xref>, <xref ref-type="bibr" rid="R23">2016</xref>) and <xref ref-type="bibr" rid="R115">Roseman et al. (2014)</xref> discovered that psychedelics affect the <italic>connectivity</italic> of the DMN, decreasing within-DMN FC (“disintegration”) while increasing DMN coupling with other resting-state networks (RSNs) (“desegregation”). Our neuroimaging meta-analysis confirms that psychedelics decrease connectivity within the DMN while elevating its connectivity with other networks. Our phenomenology meta-analysis also revealed that all psychedelics induced positive experiences of depersonalisation and derealisation, as captured by the oceanic boundlessness dimension of the 5D-ASC scale.</p><p id="P58">Nevertheless, there are many cases in which within-DMN connectivity may decrease without giving rise to the subjective effects that characterise psychedelics. Several other drugs such as amphetamines and alcohol, as well as drug addiction in general, reduce within-DMN connectivity in humans (<xref ref-type="bibr" rid="R118">Schrantee et al., 2016</xref>; <xref ref-type="bibr" rid="R150">Weber et al., 2014</xref>; <xref ref-type="bibr" rid="R154">Zhang &amp; Volkow, 2019</xref>), even though they typically do not lead to ego dissolution (<xref ref-type="bibr" rid="R40">Doss et al., 2020</xref>). Certain psychological states that exacerbate self-rumination, such as maladaptive self-focused attention, are <italic>not</italic> associated with hyperconnectivity in the DMN (<xref ref-type="bibr" rid="R44">Fang et al., 2022</xref>), and one study found that some tasks requiring self-related judgments were associated with a <italic>suppression</italic> of within-DMN connectivity (<xref ref-type="bibr" rid="R139">van Buuren et al., 2010</xref>). That being said, a recent meta-analysis of 14 studies did endorse an association between rumination and the DMN (<xref ref-type="bibr" rid="R155">Zhou et al., 2020</xref>).</p></sec><sec id="S16"><label>Section 3.2.3</label><title>Pharmacology</title><p id="P59">The results of our affinity meta-analysis aligned well with studies that performed direct comparisons of selectivity between different psychedelics (<xref ref-type="bibr" rid="R43">Eshleman et al., 2014</xref>; <xref ref-type="bibr" rid="R68">Janowsky et al., 2014</xref>; <xref ref-type="bibr" rid="R71">Kozell et al., 2023</xref>; <xref ref-type="bibr" rid="R100">Pierce &amp; Peroutka, 1989</xref>; <xref ref-type="bibr" rid="R111">Rickli et al., 2016</xref>). In line with our findings, all of these studies showed that LSD is more selective than DMT for 5-HT<sub>2A</sub>, relative to 5-HT<sub>1A</sub>. Two studies also observed that psilocin is more selective than LSD for 5-HT<sub>2A</sub> (<xref ref-type="bibr" rid="R71">Kozell et al., 2023</xref>; <xref ref-type="bibr" rid="R111">Rickli et al., 2016</xref>). Our meta-analysis demonstrated that DMT is more selective than LSD for 5-HT<sub>2C</sub>, a conclusion that is supported by three of four studies (<xref ref-type="bibr" rid="R43">Eshleman et al., 2014</xref>; <xref ref-type="bibr" rid="R68">Janowsky et al., 2014</xref>; <xref ref-type="bibr" rid="R71">Kozell et al., 2023</xref>).</p><p id="P60">Our findings about functional activity were also congruent with studies that measured the effect of multiple psychedelics on IP formation at the 5-HT<sub>2A</sub> receptor (<xref ref-type="bibr" rid="R15">Braden &amp; Nichols, 2007</xref>; <xref ref-type="bibr" rid="R43">Eshleman et al., 2014</xref>; <xref ref-type="bibr" rid="R68">Janowsky et al., 2014</xref>; <xref ref-type="bibr" rid="R71">Kozell et al., 2023</xref>). We found that LSD’s relative activity at this pathway was significantly greater than that of psilocin, which was in turn significantly larger than that of DMT. All four studies showed that LSD had higher relative activity at this pathway than DMT. Two studies also reported that psilocin’s relative activity was lower than that of LSD, but larger than that of DMT (<xref ref-type="bibr" rid="R15">Braden &amp; Nichols, 2007</xref>; <xref ref-type="bibr" rid="R71">Kozell et al., 2023</xref>).</p></sec></sec><sec id="S17"><label>Section 3.3</label><title>Sources of heterogeneity and recommendations for future research</title><p id="P61">Our systematic review of the literature has revealed several knowledge gaps in the field of psychedelic neuroscience. Firstly, some areas are lacking data. There are only three studies on the phenomenology of DMT, as evaluated with the 5D-ASC scale. In the neuroimaging literature, there are relatively few primary datasets but many secondary analyses. Of the 58 studies that we included in the neuroimaging meta-analysis, fewer than half (22) collected original data, and over a third are secondary analyses of the same two primary datasets (<xref ref-type="bibr" rid="R21">Carhart-Harris, Erritzoe, et al., 2012</xref>; <xref ref-type="bibr" rid="R23">Carhart-Harris et al., 2016</xref>) (<xref ref-type="supplementary-material" rid="SD1">Figure S2a</xref>). While the secondary analyses have offered new and compelling perspectives on brain activity under psychedelics, there need to be more replication studies in order to verify the findings from the primary datasets. Ten of the 12 studies on entropy analyse data from these primary datasets, so it is not surprising that all of them conclude that psychedelics increase entropy. If the studies had measured entropy on different primary datasets, then the results may have been different. We acknowledge this bias in our qualitative review of the entropy literature, and we also account for it in our quantitative meta-analysis of the functional connectivity (FC) literature, where we only included one study on each unique dataset.</p><p id="P62">Secondly, there are inconsistencies in experimental procedures and analysis methods. In the phenomenology literature, studies tended to administer different doses of LSD and psilocybin, such that exactly dose-equivalent comparisons of the two drugs were rare. We could not perform a meta-analysis of the BOLD activation studies because of the considerable variability in the tasks that they administered to participants. Our attempt to synthesise the FC data was hindered by the wide range of parcellations in the literature. Our meta-analysis of selective affinity in the pharmacology literature was confounded by the use of many different radioligands for labeling receptors of interest.</p><p id="P63">Our neuroimaging meta-analysis was limited by the fact that it assessed the published data rather than the raw data. It is prohibitive, time-consuming, and sometimes impossible to obtain raw data; institutions are limited by data confidentiality agreements, have lost access to old data, or are unwilling to share data for other reasons. We urge future researchers to make data publicly available, pool together raw data on psychedelics from different institutions, preprocess and parcellate it identically, and then re-apply our meta-analysis pipeline. The subsequent findings would not be confounded by different methodological choices made by different labs and would more accurately reflect the common effects of psychedelics on brain activity.</p><p id="P64">Finally, we encourage researchers to develop tools for modelling the nonlinear relationships between the pharmacology, neuroimaging, and phenomenology of psychedelics, the three hierarchical levels of analysis that are at the heart of this meta-analysis. While some researchers have attempted to examine the associations between each level (<xref ref-type="bibr" rid="R8">Ballentine et al., 2022</xref>; <xref ref-type="bibr" rid="R74">Lawn et al., 2022</xref>), their techniques are model-free and only measure <italic>correlations</italic> between the effects of psychedelics, rather than elucidating the <italic>causal mechanisms</italic> that underpin them.</p><p id="P65">Recent whole-brain models have made significant advances in discovering these causal mechanisms (see <xref ref-type="bibr" rid="R73">Kringelbach &amp; Deco (2020)</xref> for a general review). Whole-brain models consist of nodes that approximate local or mesoscopic neuronal dynamics through mean field models of coupled excitatory-inhibitory interactions (<xref ref-type="bibr" rid="R39">Deco et al., 2014</xref>; <xref ref-type="bibr" rid="R66">Honey et al., 2007</xref>) or Hopf models of bifurcations into and out of sustained oscillatory activity (<xref ref-type="bibr" rid="R38">Deco et al., 2017</xref>; <xref ref-type="bibr" rid="R46">Freyer et al., 2012</xref>), respectively. Crucially, whole-brain models have enabled researchers to identify the specific regions that should be stimulated in order to force transitions between different states of consciousness, such as from sleep to wakefulness (<xref ref-type="bibr" rid="R37">Deco et al., 2019</xref>). Whole-brain models have also been applied to psychedelics; in particular, the 5-HT<sub>2A</sub> receptor density in each area of the brain was used to fit a mean field model of fMRI data on LSD, capturing the nonlinear interactions between connectivity and the distribution of 5-HT<sub>2A</sub> receptors (<xref ref-type="bibr" rid="R36">Deco et al., 2018</xref>). This model was recently extended to determine the associations between global brain connectivity on LSD and categories of subjective experience (<xref ref-type="bibr" rid="R17">Burt et al., 2021</xref>). The model has also been applied to the relationship between neurotransmitters (namely, serotonin) and neuronal regions on psilocybin; in particular, <xref ref-type="bibr" rid="R72">Kringelbach et al. (2020)</xref> coupled a mean field model of each neuronal region to the release-and-reuptake dynamics of serotonin concentration. Importantly, this coupled neuronal-neurotransmitter model exhibited a better fit to the empirical FC than a model of solely the neuronal activity. Overall, whole-brain models display great promise for linking neurotransmitter release, which is partly determined by pharmacology, to the brain regions that causally mediate, rather than merely correlate with, the effects of psychedelics. Most recently, whole-brain models have also been combined with another cutting-edge method, turbulence, to determine the susceptibility of the brain to external stimuli under psychedelics (<xref ref-type="bibr" rid="R27">Cruzat et al., 2022</xref>).</p></sec></sec><sec id="S18" sec-type="conclusions"><label>Section 4</label><title>Conclusion</title><p id="P66">This is the first meta-analysis of the literature on the phenomenology, neuroimaging, and pharmacology of psychedelics. We assess and compare these three hierarchical levels of analysis across three different classical psychedelics: DMT, LSD, and psilocybin. Thus, we performed comparisons not only between psychedelics, but also between the levels of the hierarchy.</p><p id="P67">We found that the different levels of the hierarchy exhibited a weak one-to-one correspondence with one another. This is not surprising, as the interactions between phenomenology, neuroimaging, and pharmacology are highly non-linear and complex. We encourage future research to develop tools for modelling these relationships in order to improve our scientific understanding of psychedelics.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Materials</label><media xlink:href="EMS189365-supplement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="d46aAdEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S19"><title>Acknowledgments</title><p>K.S. is funded by the Clarendon Fund, a Department of Psychiatry studentship, the John Henry Jones Scholarship from Balliol College, and the Research Council U.K. P.M. is funded by the Wellcome Trust (grant no. 210920/Z/18/Z). K.P. is funded by the the Swiss National Science Foundation (P2ZHP1\161626). R.C-H is funded by a Ralph Metzner endowment. M.K. is supported by the Centre for Eudaimonia and Human Flourishing (funded by the Pettit and Carlsberg Foundations) and Center for Music in the Brain (funded by the Danish National Research Foundation, DNRF117).</p></ack><sec id="S20" sec-type="data-availability"><title>Code Availability</title><p id="P68">Code is available upon request by emailing the corresponding author: <email>kenneth.shinozuka@psych.ox.ac.uk</email></p></sec><fn-group><fn id="FN1" fn-type="conflict"><p id="P69">Competing Interests Statement</p><p id="P70">The authors have no conflicts of interest to declare.</p></fn></fn-group><ref-list><ref id="R1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aday</surname><given-names>JS</given-names></name><name><surname>Davis</surname><given-names>AK</given-names></name><name><surname>Mitzkovitz</surname><given-names>CM</given-names></name><name><surname>Bloesch</surname><given-names>EK</given-names></name><name><surname>Davoli</surname><given-names>CC</given-names></name></person-group><article-title>Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects</article-title><source>ACS Pharmacology &amp; Translational Science</source><year>2021</year><volume>4</volume><issue>2</issue><fpage>424</fpage><lpage>435</lpage><pub-id pub-id-type="pmcid">PMC8033773</pub-id><pub-id pub-id-type="pmid">33860172</pub-id><pub-id pub-id-type="doi">10.1021/acsptsci.1c00014</pub-id></element-citation></ref><ref id="R2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghajanian</surname><given-names>GK</given-names></name><name><surname>Marek</surname><given-names>GJ</given-names></name></person-group><article-title>Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells</article-title><source>Neuropharmacology</source><year>1997</year><volume>36</volume><issue>4–5</issue><fpage>589</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">9225284</pub-id></element-citation></ref><ref id="R3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghajanian</surname><given-names>GK</given-names></name><name><surname>Marek</surname><given-names>GJ</given-names></name></person-group><article-title>Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release</article-title><source>Brain Research</source><year>1999</year><volume>825</volume><issue>1–2</issue><fpage>161</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">10216183</pub-id></element-citation></ref><ref id="R4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleksandrova</surname><given-names>LR</given-names></name><name><surname>Phillips</surname><given-names>AG</given-names></name></person-group><article-title>Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics</article-title><source>Trends in Pharmacological Sciences</source><year>2021</year><volume>42</volume><issue>11</issue><fpage>929</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">34565579</pub-id></element-citation></ref><ref id="R5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andresen</surname><given-names>BT</given-names></name></person-group><article-title>A Pharmacological Primer of Biased Agonism</article-title><source>Endocrine, Metabolic &amp; Immune Disorders Drug Targets</source><year>2011</year><volume>11</volume><issue>2</issue><fpage>92</fpage><lpage>98</lpage><pub-id pub-id-type="pmcid">PMC3182416</pub-id><pub-id pub-id-type="pmid">21476970</pub-id><pub-id pub-id-type="doi">10.2174/187153011795564179</pub-id></element-citation></ref><ref id="R6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araújo</surname><given-names>AM</given-names></name><name><surname>Carvalho</surname><given-names>F</given-names></name><name><surname>de Bastos</surname><given-names>ML</given-names></name><name><surname>Guedes de Pinho</surname><given-names>P</given-names></name><name><surname>Carvalho</surname><given-names>M</given-names></name></person-group><article-title>The hallucinogenic world of tryptamines: An updated review</article-title><source>Archives of Toxicology</source><year>2015</year><volume>89</volume><issue>8</issue><fpage>1151</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">25877327</pub-id></element-citation></ref><ref id="R7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atasoy</surname><given-names>S</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Kringelbach</surname><given-names>ML</given-names></name><name><surname>Deco</surname><given-names>G</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD</article-title><source>Scientific Reports</source><year>2017</year><volume>7</volume><issue>1</issue><comment>Article 1</comment><pub-id pub-id-type="pmcid">PMC5732294</pub-id><pub-id pub-id-type="pmid">29247209</pub-id><pub-id pub-id-type="doi">10.1038/s41598-017-17546-0</pub-id></element-citation></ref><ref id="R8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballentine</surname><given-names>G</given-names></name><name><surname>Friedman</surname><given-names>SF</given-names></name><name><surname>Bzdok</surname><given-names>D</given-names></name></person-group><article-title>Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences</article-title><source>Science Advances</source><year>2022</year><volume>8</volume><issue>11</issue><elocation-id>eabl6989</elocation-id><pub-id pub-id-type="pmcid">PMC8926331</pub-id><pub-id pub-id-type="pmid">35294242</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.abl6989</pub-id></element-citation></ref><ref id="R9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>FS</given-names></name><name><surname>Doss</surname><given-names>MK</given-names></name><name><surname>Sepeda</surname><given-names>ND</given-names></name><name><surname>Pekar</surname><given-names>JJ</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group><article-title>Emotions and brain function are altered up to one month after a single high dose of psilocybin</article-title><source>Scientific Reports</source><year>2020</year><volume>10</volume><issue>1</issue><elocation-id>2214</elocation-id><pub-id pub-id-type="pmcid">PMC7010702</pub-id><pub-id pub-id-type="pmid">32042038</pub-id><pub-id pub-id-type="doi">10.1038/s41598-020-59282-y</pub-id></element-citation></ref><ref id="R10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>FS</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group><article-title>Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin</article-title><source>Journal of Psychopharmacology</source><year>2015</year><volume>29</volume><issue>11</issue><fpage>1182</fpage><lpage>1190</lpage><pub-id pub-id-type="pmcid">PMC5203697</pub-id><pub-id pub-id-type="pmid">26442957</pub-id><pub-id pub-id-type="doi">10.1177/0269881115609019</pub-id></element-citation></ref><ref id="R11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>FS</given-names></name><name><surname>Krimmel</surname><given-names>SR</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Seminowicz</surname><given-names>DA</given-names></name><name><surname>Mathur</surname><given-names>BN</given-names></name></person-group><article-title>Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention</article-title><source>NeuroImage</source><year>2020</year><volume>218</volume><elocation-id>116980</elocation-id><pub-id pub-id-type="pmcid">PMC10792549</pub-id><pub-id pub-id-type="pmid">32454209</pub-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.116980</pub-id></element-citation></ref><ref id="R12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beliveau</surname><given-names>V</given-names></name><name><surname>Ganz</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Ozenne</surname><given-names>B</given-names></name><name><surname>Højgaard</surname><given-names>L</given-names></name><name><surname>Fisher</surname><given-names>PM</given-names></name><name><surname>Svarer</surname><given-names>C</given-names></name><name><surname>Greve</surname><given-names>DN</given-names></name><name><surname>Knudsen</surname><given-names>GM</given-names></name></person-group><article-title>A High-Resolution In Vivo Atlas of the Human Brain’s Serotonin System</article-title><source>The Journal of Neuroscience: The Official Journal of the Society for Neuroscience</source><year>2017</year><volume>37</volume><issue>1</issue><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="pmcid">PMC5214625</pub-id><pub-id pub-id-type="pmid">28053035</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2830-16.2016</pub-id></element-citation></ref><ref id="R13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>N</given-names></name></person-group><article-title>Evidence against epiphenomenalism</article-title><source>Behavioral and Brain Sciences</source><year>1991</year><volume>14</volume><issue>4</issue><fpage>670</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1017/S0140525X0007179X</pub-id></element-citation></ref><ref id="R14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohn</surname><given-names>LM</given-names></name><name><surname>Schmid</surname><given-names>CL</given-names></name></person-group><article-title>Serotonin receptor signaling and regulation via β-arrestins</article-title><source>Critical Reviews in Biochemistry and Molecular Biology</source><year>2010</year><volume>45</volume><issue>6</issue><fpage>555</fpage><pub-id pub-id-type="pmcid">PMC4776633</pub-id><pub-id pub-id-type="pmid">20925600</pub-id><pub-id pub-id-type="doi">10.3109/10409238.2010.516741</pub-id></element-citation></ref><ref id="R15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braden</surname><given-names>MR</given-names></name><name><surname>Nichols</surname><given-names>DE</given-names></name></person-group><article-title>Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor</article-title><source>Molecular Pharmacology</source><year>2007</year><volume>72</volume><issue>5</issue><fpage>1200</fpage><lpage>1209</lpage><pub-id pub-id-type="pmid">17715398</pub-id></element-citation></ref><ref id="R16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>SD</given-names></name><name><surname>Freeman</surname><given-names>S</given-names></name><name><surname>McGagh</surname><given-names>P</given-names></name><name><surname>Abdul-Halim</surname><given-names>N</given-names></name><name><surname>Alder</surname><given-names>JF</given-names></name></person-group><article-title>An analytical perspective on favoured synthetic routes to the psychoactive tryptamines</article-title><source>Journal of Pharmaceutical and Biomedical Analysis</source><year>2004</year><volume>36</volume><issue>4</issue><fpage>675</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">15533659</pub-id></element-citation></ref><ref id="R17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burt</surname><given-names>JB</given-names></name><name><surname>Preller</surname><given-names>KH</given-names></name><name><surname>Demirtas</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>JL</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Anticevic</surname><given-names>A</given-names></name><name><surname>Murray</surname><given-names>JD</given-names></name></person-group><article-title>Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD</article-title><source>eLife</source><year>2021</year><volume>10</volume><elocation-id>e69320</elocation-id><pub-id pub-id-type="pmcid">PMC8315798</pub-id><pub-id pub-id-type="pmid">34313217</pub-id><pub-id pub-id-type="doi">10.7554/eLife.69320</pub-id></element-citation></ref><ref id="R18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canal</surname><given-names>CE</given-names></name><name><surname>Murnane</surname><given-names>KS</given-names></name></person-group><article-title>The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens</article-title><source>Journal of Psychopharmacology</source><year>2017</year><volume>31</volume><issue>1</issue><fpage>127</fpage><lpage>143</lpage><pub-id pub-id-type="pmcid">PMC5445387</pub-id><pub-id pub-id-type="pmid">27903793</pub-id><pub-id pub-id-type="doi">10.1177/0269881116677104</pub-id></element-citation></ref><ref id="R19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbonaro</surname><given-names>TM</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Hurwitz</surname><given-names>E</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group><article-title>Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Similarities and differences in subjective experiences</article-title><source>Psychopharmacology</source><year>2018</year><volume>235</volume><issue>2</issue><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="pmcid">PMC6645364</pub-id><pub-id pub-id-type="pmid">29116367</pub-id><pub-id pub-id-type="doi">10.1007/s00213-017-4769-4</pub-id></element-citation></ref><ref id="R20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>The entropic brain—Revisited</article-title><source>Neuropharmacology</source><year>2018</year><volume>142</volume><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">29548884</pub-id></element-citation></ref><ref id="R21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Erritzoe</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>T</given-names></name><name><surname>Stone</surname><given-names>JM</given-names></name><name><surname>Reed</surname><given-names>LJ</given-names></name><name><surname>Colasanti</surname><given-names>A</given-names></name><name><surname>Tyacke</surname><given-names>RJ</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>Malizia</surname><given-names>AL</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Hobden</surname><given-names>P</given-names></name><etal/></person-group><article-title>Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin</article-title><source>Proceedings of the National Academy of Sciences</source><year>2012</year><volume>109</volume><issue>6</issue><fpage>2138</fpage><lpage>2143</lpage><pub-id pub-id-type="pmcid">PMC3277566</pub-id><pub-id pub-id-type="pmid">22308440</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1119598109</pub-id></element-citation></ref><ref id="R22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>Erritzoe</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>TM</given-names></name><name><surname>Stone</surname><given-names>JM</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Sharp</surname><given-names>DJ</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Wise</surname><given-names>RG</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name></person-group><article-title>Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis</article-title><source>Schizophrenia Bulletin</source><year>2013</year><volume>39</volume><issue>6</issue><fpage>1343</fpage><lpage>1351</lpage><pub-id pub-id-type="pmcid">PMC3796071</pub-id><pub-id pub-id-type="pmid">23044373</pub-id><pub-id pub-id-type="doi">10.1093/schbul/sbs117</pub-id></element-citation></ref><ref id="R23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Muthukumaraswamy</surname><given-names>S</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Droog</surname><given-names>W</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Tagliazucchi</surname><given-names>E</given-names></name><name><surname>Schenberg</surname><given-names>EE</given-names></name><name><surname>Nest</surname><given-names>T</given-names></name><name><surname>Orban</surname><given-names>C</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><etal/></person-group><article-title>Neural correlates of the LSD experience revealed by multimodal neuroimaging</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2016</year><volume>113</volume><issue>17</issue><fpage>4853</fpage><lpage>4858</lpage><pub-id pub-id-type="pmcid">PMC4855588</pub-id><pub-id pub-id-type="pmid">27071089</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1518377113</pub-id></element-citation></ref><ref id="R24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Bolstridge</surname><given-names>M</given-names></name><name><surname>Demetriou</surname><given-names>L</given-names></name><name><surname>Pannekoek</surname><given-names>JN</given-names></name><name><surname>Wall</surname><given-names>MB</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>McGonigle</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><etal/></person-group><article-title>Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms</article-title><source>Scientific Reports</source><year>2017</year><volume>7</volume><issue>1</issue><comment>Article 1</comment><pub-id pub-id-type="pmcid">PMC5640601</pub-id><pub-id pub-id-type="pmid">29030624</pub-id><pub-id pub-id-type="doi">10.1038/s41598-017-13282-7</pub-id></element-citation></ref><ref id="R25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>R</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>Hellyer</surname><given-names>P</given-names></name><name><surname>Shanahan</surname><given-names>M</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Tagliazucchi</surname><given-names>E</given-names></name><name><surname>Chialvo</surname><given-names>D</given-names></name><name><surname>Nutt</surname><given-names>D</given-names></name></person-group><article-title>The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs</article-title><source>Frontiers in Human Neuroscience</source><year>2014</year><volume>8</volume><pub-id pub-id-type="pmcid">PMC3909994</pub-id><pub-id pub-id-type="pmid">24550805</pub-id><pub-id pub-id-type="doi">10.3389/fnhum.2014.00020</pub-id></element-citation></ref><ref id="R26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>JR</given-names></name><name><surname>Presti</surname><given-names>DE</given-names></name><name><surname>Baggott</surname><given-names>MJ</given-names></name></person-group><article-title>Quantitative Analysis of Narrative Reports of Psychedelic Drugs</article-title><year>2012</year><elocation-id>arXiv:1206.0312</elocation-id><source>arXiv</source><pub-id pub-id-type="doi">10.48550/arXiv.1206.0312</pub-id></element-citation></ref><ref id="R27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruzat</surname><given-names>J</given-names></name><name><surname>Perl</surname><given-names>YS</given-names></name><name><surname>Escrichs</surname><given-names>A</given-names></name><name><surname>Vohryzek</surname><given-names>J</given-names></name><name><surname>Timmermann</surname><given-names>C</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Luppi</surname><given-names>AI</given-names></name><name><surname>Ibañez</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>D</given-names></name><name><surname>Carhart-Harris</surname><given-names>R</given-names></name><name><surname>Tagliazucchi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effects of classic psychedelic drugs on turbulent signatures in brain dynamics</article-title><source>Network Neuroscience</source><year>2022</year><volume>6</volume><issue>4</issue><fpage>1104</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1162/netn_a_00250</pub-id></element-citation></ref><ref id="R28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>R</given-names></name><name><surname>Larkin</surname><given-names>TE</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Tarnal</surname><given-names>V</given-names></name><name><surname>Picton</surname><given-names>P</given-names></name><name><surname>Vlisides</surname><given-names>PE</given-names></name><name><surname>Janke</surname><given-names>E</given-names></name><name><surname>McKinney</surname><given-names>A</given-names></name><name><surname>Hudetz</surname><given-names>AG</given-names></name><name><surname>Harris</surname><given-names>RE</given-names></name><name><surname>Mashour</surname><given-names>GA</given-names></name></person-group><article-title>Classical and non-classical psychedelic drugs induce common network changes in human cortex</article-title><source>NeuroImage</source><year>2023</year><volume>273</volume><elocation-id>120097</elocation-id><pub-id pub-id-type="pmid">37031827</pub-id></element-citation></ref><ref id="R29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>CG</given-names></name><name><surname>Harrison</surname><given-names>BJ</given-names></name></person-group><article-title>The brain’s center of gravity: How the default mode network helps us to understand the self</article-title><source>World Psychiatry</source><year>2018</year><volume>17</volume><issue>3</issue><fpage>278</fpage><lpage>279</lpage><pub-id pub-id-type="pmcid">PMC6127769</pub-id><pub-id pub-id-type="pmid">30192084</pub-id><pub-id pub-id-type="doi">10.1002/wps.20553</pub-id></element-citation></ref><ref id="R30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>CG</given-names></name><name><surname>Pujol</surname><given-names>J</given-names></name><name><surname>Harrison</surname><given-names>BJ</given-names></name></person-group><article-title>Mapping the self in the brain’s default mode network</article-title><source>NeuroImage</source><year>2016</year><volume>132</volume><fpage>390</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">26892855</pub-id></element-citation></ref><ref id="R31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>AK</given-names></name><name><surname>Barrett</surname><given-names>FS</given-names></name><name><surname>So</surname><given-names>S</given-names></name><name><surname>Gukasyan</surname><given-names>N</given-names></name><name><surname>Swift</surname><given-names>TC</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group><article-title>Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD</article-title><source>Journal of Psychopharmacology (Oxford, England)</source><year>2021</year><volume>35</volume><issue>4</issue><fpage>437</fpage><lpage>446</lpage><pub-id pub-id-type="pmcid">PMC8056708</pub-id><pub-id pub-id-type="pmid">33427007</pub-id><pub-id pub-id-type="doi">10.1177/0269881120967878</pub-id></element-citation></ref><ref id="R32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daws</surname><given-names>RE</given-names></name><name><surname>Timmermann</surname><given-names>C</given-names></name><name><surname>Giribaldi</surname><given-names>B</given-names></name><name><surname>Sexton</surname><given-names>JD</given-names></name><name><surname>Wall</surname><given-names>MB</given-names></name><name><surname>Erritzoe</surname><given-names>D</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Nutt</surname><given-names>D</given-names></name><name><surname>Carhart-Harris</surname><given-names>R</given-names></name></person-group><article-title>Increased global integration in the brain after psilocybin therapy for depression</article-title><source>Nature Medicine</source><year>2022</year><volume>28</volume><issue>4</issue><comment>Article 4</comment><pub-id pub-id-type="pmid">35411074</pub-id></element-citation></ref><ref id="R33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Almeida</surname><given-names>J</given-names></name><name><surname>Mengod</surname><given-names>G</given-names></name></person-group><article-title>Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT(2A) receptors in human and monkey prefrontal cortex</article-title><source>Journal of Neurochemistry</source><year>2007</year><volume>103</volume><issue>2</issue><fpage>475</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">17635672</pub-id></element-citation></ref><ref id="R34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>PG</given-names></name><name><surname>Ramos</surname><given-names>MLS</given-names></name><name><surname>Amaro</surname><given-names>AJ</given-names></name><name><surname>Dias</surname><given-names>RA</given-names></name><name><surname>Vieira</surname><given-names>SI</given-names></name></person-group><article-title>Gi/o-Protein Coupled Receptors in the Aging Brain</article-title><source>Frontiers in Aging Neuroscience</source><year>2019</year><volume>11</volume><pub-id pub-id-type="pmcid">PMC6492497</pub-id><pub-id pub-id-type="pmid">31105551</pub-id><pub-id pub-id-type="doi">10.3389/fnagi.2019.00089</pub-id></element-citation></ref><ref id="R35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vos</surname><given-names>CMH</given-names></name><name><surname>Mason</surname><given-names>NL</given-names></name><name><surname>Kuypers</surname><given-names>KPC</given-names></name></person-group><article-title>Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics</article-title><source>Frontiers in Psychiatry</source><year>2021</year><volume>12</volume><pub-id pub-id-type="pmcid">PMC8461007</pub-id><pub-id pub-id-type="pmid">34566723</pub-id><pub-id pub-id-type="doi">10.3389/fpsyt.2021.724606</pub-id></element-citation></ref><ref id="R36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deco</surname><given-names>G</given-names></name><name><surname>Cruzat</surname><given-names>J</given-names></name><name><surname>Cabral</surname><given-names>J</given-names></name><name><surname>Knudsen</surname><given-names>GM</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Whybrow</surname><given-names>PC</given-names></name><name><surname>Logothetis</surname><given-names>NK</given-names></name><name><surname>Kringelbach</surname><given-names>ML</given-names></name></person-group><article-title>Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD</article-title><source>Current Biology</source><year>2018</year><volume>28</volume><issue>19</issue><fpage>3065</fpage><lpage>3074</lpage><elocation-id>e6</elocation-id><pub-id pub-id-type="pmid">30270185</pub-id></element-citation></ref><ref id="R37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deco</surname><given-names>G</given-names></name><name><surname>Cruzat</surname><given-names>J</given-names></name><name><surname>Cabral</surname><given-names>J</given-names></name><name><surname>Tagliazucchi</surname><given-names>E</given-names></name><name><surname>Laufs</surname><given-names>H</given-names></name><name><surname>Logothetis</surname><given-names>NK</given-names></name><name><surname>Kringelbach</surname><given-names>ML</given-names></name></person-group><article-title>Awakening: Predicting external stimulation to force transitions between different brain states</article-title><source>Proceedings of the National Academy of Sciences</source><year>2019</year><volume>116</volume><issue>36</issue><fpage>18088</fpage><lpage>18097</lpage><pub-id pub-id-type="pmcid">PMC6731634</pub-id><pub-id pub-id-type="pmid">31427539</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1905534116</pub-id></element-citation></ref><ref id="R38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deco</surname><given-names>G</given-names></name><name><surname>Kringelbach</surname><given-names>ML</given-names></name><name><surname>Jirsa</surname><given-names>VK</given-names></name><name><surname>Ritter</surname><given-names>P</given-names></name></person-group><article-title>The dynamics of resting fluctuations in the brain: Metastability and its dynamical cortical core</article-title><source>Scientific Reports</source><year>2017</year><volume>7</volume><issue>1</issue><elocation-id>3095</elocation-id><pub-id pub-id-type="pmcid">PMC5465179</pub-id><pub-id pub-id-type="pmid">28596608</pub-id><pub-id pub-id-type="doi">10.1038/s41598-017-03073-5</pub-id></element-citation></ref><ref id="R39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deco</surname><given-names>G</given-names></name><name><surname>Ponce-Alvarez</surname><given-names>A</given-names></name><name><surname>Hagmann</surname><given-names>P</given-names></name><name><surname>Romani</surname><given-names>GL</given-names></name><name><surname>Mantini</surname><given-names>D</given-names></name><name><surname>Corbetta</surname><given-names>M</given-names></name></person-group><article-title>How Local Excitation–Inhibition Ratio Impacts the Whole Brain Dynamics</article-title><source>Journal of Neuroscience</source><year>2014</year><volume>34</volume><issue>23</issue><fpage>7886</fpage><lpage>7898</lpage><pub-id pub-id-type="pmcid">PMC4044249</pub-id><pub-id pub-id-type="pmid">24899711</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5068-13.2014</pub-id></element-citation></ref><ref id="R40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doss</surname><given-names>MK</given-names></name><name><surname>May</surname><given-names>DG</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Clifton</surname><given-names>JM</given-names></name><name><surname>Hedrick</surname><given-names>SL</given-names></name><name><surname>Prisinzano</surname><given-names>TE</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Barrett</surname><given-names>FS</given-names></name></person-group><article-title>The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain</article-title><source>Scientific Reports</source><year>2020</year><volume>10</volume><issue>1</issue><comment>Article 1</comment><pub-id pub-id-type="pmcid">PMC7532139</pub-id><pub-id pub-id-type="pmid">33009457</pub-id><pub-id pub-id-type="doi">10.1038/s41598-020-73216-8</pub-id></element-citation></ref><ref id="R41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doss</surname><given-names>MK</given-names></name><name><surname>Považan</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>MD</given-names></name><name><surname>Sepeda</surname><given-names>ND</given-names></name><name><surname>Davis</surname><given-names>AK</given-names></name><name><surname>Finan</surname><given-names>PH</given-names></name><name><surname>Smith</surname><given-names>GS</given-names></name><name><surname>Pekar</surname><given-names>JJ</given-names></name><name><surname>Barker</surname><given-names>PB</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Barrett</surname><given-names>FS</given-names></name></person-group><article-title>Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder</article-title><source>Translational Psychiatry</source><year>2021</year><volume>11</volume><issue>1</issue><comment>Article 1</comment><pub-id pub-id-type="pmcid">PMC8575795</pub-id><pub-id pub-id-type="pmid">34750350</pub-id><pub-id pub-id-type="doi">10.1038/s41398-021-01706-y</pub-id></element-citation></ref><ref id="R42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duerler</surname><given-names>P</given-names></name><name><surname>Brem</surname><given-names>S</given-names></name><name><surname>Fraga-González</surname><given-names>G</given-names></name><name><surname>Neef</surname><given-names>T</given-names></name><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>Zeidman</surname><given-names>P</given-names></name><name><surname>Stämpfli</surname><given-names>P</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Preller</surname><given-names>KH</given-names></name></person-group><article-title>Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study</article-title><source>Cerebral Cortex (New York, N.Y.: 1991)</source><year>2021</year><volume>32</volume><issue>1</issue><fpage>186</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">34255821</pub-id></element-citation></ref><ref id="R43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eshleman</surname><given-names>AJ</given-names></name><name><surname>Forster</surname><given-names>MJ</given-names></name><name><surname>Wolfrum</surname><given-names>KM</given-names></name><name><surname>Johnson</surname><given-names>RA</given-names></name><name><surname>Janowsky</surname><given-names>A</given-names></name><name><surname>Gatch</surname><given-names>MB</given-names></name></person-group><article-title>Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: Mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function</article-title><source>Psychopharmacology</source><year>2014</year><volume>231</volume><issue>5</issue><fpage>875</fpage><lpage>888</lpage><pub-id pub-id-type="pmcid">PMC3945162</pub-id><pub-id pub-id-type="pmid">24142203</pub-id><pub-id pub-id-type="doi">10.1007/s00213-013-3303-6</pub-id></element-citation></ref><ref id="R44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>A</given-names></name><name><surname>Baran</surname><given-names>B</given-names></name><name><surname>Beatty</surname><given-names>CC</given-names></name><name><surname>Mosley</surname><given-names>J</given-names></name><name><surname>Feusner</surname><given-names>JD</given-names></name><name><surname>Phan</surname><given-names>KL</given-names></name><name><surname>Wilhelm</surname><given-names>S</given-names></name><name><surname>Manoach</surname><given-names>DS</given-names></name></person-group><article-title>Maladaptive self-focused attention and default mode network connectivity: A transdiagnostic investigation across social anxiety and body dysmorphic disorders</article-title><source>Social Cognitive and Affective Neuroscience</source><year>2022</year><volume>17</volume><issue>7</issue><fpage>645</fpage><lpage>654</lpage><pub-id pub-id-type="pmcid">PMC9250304</pub-id><pub-id pub-id-type="pmid">34875086</pub-id><pub-id pub-id-type="doi">10.1093/scan/nsab130</pub-id></element-citation></ref><ref id="R45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantegrossi</surname><given-names>WE</given-names></name><name><surname>Murnane</surname><given-names>KS</given-names></name><name><surname>Reissig</surname><given-names>CJ</given-names></name></person-group><article-title>The behavioral pharmacology of hallucinogens</article-title><source>Biochemical Pharmacology</source><year>2008</year><volume>75</volume><issue>1</issue><fpage>17</fpage><lpage>33</lpage><pub-id pub-id-type="pmcid">PMC2247373</pub-id><pub-id pub-id-type="pmid">17977517</pub-id><pub-id pub-id-type="doi">10.1016/j.bcp.2007.07.018</pub-id></element-citation></ref><ref id="R46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freyer</surname><given-names>F</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Ritter</surname><given-names>P</given-names></name><name><surname>Breakspear</surname><given-names>M</given-names></name></person-group><article-title>A Canonical Model of Multistability and Scale-Invariance in Biological Systems</article-title><source>PLOS Computational Biology</source><year>2012</year><volume>8</volume><issue>8</issue><elocation-id>e1002634</elocation-id><pub-id pub-id-type="pmcid">PMC3415415</pub-id><pub-id pub-id-type="pmid">22912567</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002634</pub-id></element-citation></ref><ref id="R47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fribourg</surname><given-names>M</given-names></name><name><surname>Moreno</surname><given-names>JL</given-names></name><name><surname>Holloway</surname><given-names>T</given-names></name><name><surname>Provasi</surname><given-names>D</given-names></name><name><surname>Baki</surname><given-names>L</given-names></name><name><surname>Mahajan</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>G</given-names></name><name><surname>Adney</surname><given-names>SK</given-names></name><name><surname>Hatcher</surname><given-names>C</given-names></name><name><surname>Eltit</surname><given-names>JM</given-names></name><name><surname>Ruta</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs</article-title><source>Cell</source><year>2011</year><volume>147</volume><issue>5</issue><fpage>1011</fpage><lpage>1023</lpage><pub-id pub-id-type="pmcid">PMC3255795</pub-id><pub-id pub-id-type="pmid">22118459</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2011.09.055</pub-id></element-citation></ref><ref id="R48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>ACM</given-names></name><name><surname>de Maia</surname><given-names>LO</given-names></name></person-group><article-title>The therapeutic potential of psychedelic substances in Hospice and Palliative Care</article-title><source>Progress in Palliative Care</source><year>2022</year><volume>30</volume><issue>1</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1080/09699260.2022.2001140</pub-id></element-citation></ref><ref id="R49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>EE</given-names></name><name><surname>Smith</surname><given-names>RL</given-names></name><name><surname>Sanders-Bush</surname><given-names>E</given-names></name></person-group><article-title>Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane</article-title><source>Neuropharmacology</source><year>2007</year><volume>52</volume><issue>8</issue><fpage>1671</fpage><lpage>1677</lpage><pub-id pub-id-type="pmcid">PMC1987710</pub-id><pub-id pub-id-type="pmid">17493641</pub-id><pub-id pub-id-type="doi">10.1016/j.neuropharm.2007.03.013</pub-id></element-citation></ref><ref id="R50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girn</surname><given-names>M</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Bernhardt</surname><given-names>B</given-names></name><name><surname>Smallwood</surname><given-names>J</given-names></name><name><surname>Carhart-Harris</surname><given-names>R</given-names></name><name><surname>Nathan Spreng</surname><given-names>R</given-names></name></person-group><article-title>Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex</article-title><source>NeuroImage</source><year>2022</year><volume>256</volume><elocation-id>119220</elocation-id><pub-id pub-id-type="pmid">35483649</pub-id></element-citation></ref><ref id="R51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giulietti</surname><given-names>M</given-names></name><name><surname>Vivenzio</surname><given-names>V</given-names></name><name><surname>Piva</surname><given-names>F</given-names></name><name><surname>Principato</surname><given-names>G</given-names></name><name><surname>Bellantuono</surname><given-names>C</given-names></name><name><surname>Nardi</surname><given-names>B</given-names></name></person-group><article-title>How much do we know about the coupling of G-proteins to serotonin receptors?</article-title><source>Molecular Brain</source><year>2014</year><volume>7</volume><issue>1</issue><fpage>49</fpage><pub-id pub-id-type="pmcid">PMC4105882</pub-id><pub-id pub-id-type="pmid">25011628</pub-id><pub-id pub-id-type="doi">10.1186/s13041-014-0049-y</pub-id></element-citation></ref><ref id="R52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glennon</surname><given-names>RA</given-names></name><name><surname>Titeler</surname><given-names>M</given-names></name><name><surname>McKenney</surname><given-names>JD</given-names></name></person-group><article-title>Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents</article-title><source>Life Sciences</source><year>1984</year><volume>35</volume><issue>25</issue><fpage>2505</fpage><lpage>2511</lpage><pub-id pub-id-type="pmid">6513725</pub-id></element-citation></ref><ref id="R53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González-Maeso</surname><given-names>J</given-names></name><name><surname>Weisstaub</surname><given-names>NV</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Ivic</surname><given-names>L</given-names></name><name><surname>Ang</surname><given-names>R</given-names></name><name><surname>Lira</surname><given-names>A</given-names></name><name><surname>Bradley-Moore</surname><given-names>M</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Sealfon</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior</article-title><source>Neuron</source><year>2007</year><volume>53</volume><issue>3</issue><fpage>439</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">17270739</pub-id></element-citation></ref><ref id="R54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouzoulis-Mayfrank</surname><given-names>E</given-names></name><name><surname>Schreckenberger</surname><given-names>M</given-names></name><name><surname>Sabri</surname><given-names>O</given-names></name><name><surname>Arning</surname><given-names>C</given-names></name><name><surname>Thelen</surname><given-names>B</given-names></name><name><surname>Spitzer</surname><given-names>M</given-names></name><name><surname>Kovar</surname><given-names>K-A</given-names></name><name><surname>Hermle</surname><given-names>L</given-names></name><name><surname>Büll</surname><given-names>U</given-names></name><name><surname>Sass</surname><given-names>H</given-names></name></person-group><article-title>Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG</article-title><source>Neuropsychopharmacology</source><year>1999</year><volume>20</volume><issue>6</issue><comment>Article 6</comment><pub-id pub-id-type="pmid">10327426</pub-id></element-citation></ref><ref id="R55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Hurwitz</surname><given-names>ES</given-names></name><name><surname>Davis</surname><given-names>AK</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Jesse</surname><given-names>R</given-names></name></person-group><article-title>Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT</article-title><source>PLOS ONE</source><year>2019</year><volume>14</volume><issue>4</issue><elocation-id>e0214377</elocation-id><pub-id pub-id-type="pmcid">PMC6478303</pub-id><pub-id pub-id-type="pmid">31013281</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0214377</pub-id></element-citation></ref><ref id="R56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Richards</surname><given-names>WA</given-names></name><name><surname>Richards</surname><given-names>BD</given-names></name><name><surname>Jesse</surname><given-names>R</given-names></name><name><surname>MacLean</surname><given-names>KA</given-names></name><name><surname>Barrett</surname><given-names>FS</given-names></name><name><surname>Cosimano</surname><given-names>MP</given-names></name><name><surname>Klinedinst</surname><given-names>MA</given-names></name></person-group><article-title>Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors</article-title><source>Journal of Psychopharmacology (Oxford, England)</source><year>2018</year><volume>32</volume><issue>1</issue><fpage>49</fpage><lpage>69</lpage><pub-id pub-id-type="pmcid">PMC5772431</pub-id><pub-id pub-id-type="pmid">29020861</pub-id><pub-id pub-id-type="doi">10.1177/0269881117731279</pub-id></element-citation></ref><ref id="R57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurevich</surname><given-names>EV</given-names></name><name><surname>Gainetdinov</surname><given-names>RR</given-names></name><name><surname>Gurevich</surname><given-names>VV</given-names></name></person-group><article-title>G protein-coupled receptor kinases as regulators of dopamine receptor functions</article-title><source>Pharmacological Research</source><year>2016</year><volume>111</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmcid">PMC5079267</pub-id><pub-id pub-id-type="pmid">27178731</pub-id><pub-id pub-id-type="doi">10.1016/j.phrs.2016.05.010</pub-id></element-citation></ref><ref id="R58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamada</surname><given-names>S</given-names></name><name><surname>Senzaki</surname><given-names>K</given-names></name><name><surname>Hamaguchi-Hamada</surname><given-names>K</given-names></name><name><surname>Tabuchi</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Yoshikawa</surname><given-names>S</given-names></name><name><surname>Okano</surname><given-names>H</given-names></name><name><surname>Okado</surname><given-names>N</given-names></name></person-group><article-title>Localization of 5-HT2A receptor in rat cerebral cortex and olfactory system revealed by immunohistochemistry using two antibodies raised in rabbit and chicken</article-title><source>Brain Research Molecular Brain Research</source><year>1998</year><volume>54</volume><issue>2</issue><fpage>199</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">9555012</pub-id></element-citation></ref><ref id="R59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>JY</given-names></name><name><surname>Shafiei</surname><given-names>G</given-names></name><name><surname>Markello</surname><given-names>RD</given-names></name><name><surname>Smart</surname><given-names>K</given-names></name><name><surname>Cox</surname><given-names>SML</given-names></name><name><surname>Nørgaard</surname><given-names>M</given-names></name><name><surname>Beliveau</surname><given-names>V</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Gallezot</surname><given-names>J-D</given-names></name><name><surname>Aumont</surname><given-names>É</given-names></name><name><surname>Servaes</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mapping neurotransmitter systems to the structural and functional organization of the human neocortex</article-title><source>Nature Neuroscience</source><year>2022</year><volume>25</volume><issue>11</issue><comment>Article 11</comment><pub-id pub-id-type="pmcid">PMC9630096</pub-id><pub-id pub-id-type="pmid">36303070</pub-id><pub-id pub-id-type="doi">10.1038/s41593-022-01186-3</pub-id></element-citation></ref><ref id="R60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasler</surname><given-names>F</given-names></name><name><surname>Grimberg</surname><given-names>U</given-names></name><name><surname>Benz</surname><given-names>MA</given-names></name><name><surname>Huber</surname><given-names>T</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study</article-title><source>Psychopharmacology</source><year>2004</year><volume>172</volume><issue>2</issue><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">14615876</pub-id></element-citation></ref><ref id="R61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haufe</surname><given-names>S</given-names></name><name><surname>DeGuzman</surname><given-names>P</given-names></name><name><surname>Henin</surname><given-names>S</given-names></name><name><surname>Arcaro</surname><given-names>M</given-names></name><name><surname>Honey</surname><given-names>CJ</given-names></name><name><surname>Hasson</surname><given-names>U</given-names></name><name><surname>Parra</surname><given-names>LC</given-names></name></person-group><article-title>Elucidating relations between fMRI, ECoG, and EEG through a common natural stimulus</article-title><source>NeuroImage</source><year>2018</year><volume>179</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="pmcid">PMC6063527</pub-id><pub-id pub-id-type="pmid">29902585</pub-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2018.06.016</pub-id></element-citation></ref><ref id="R62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendricks</surname><given-names>PS</given-names></name></person-group><article-title>Awe: A putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy</article-title><source>International Review of Psychiatry</source><year>2018</year><volume>30</volume><issue>4</issue><fpage>331</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">30260256</pub-id></element-citation></ref><ref id="R63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermle</surname><given-names>L</given-names></name><name><surname>Fünfgeld</surname><given-names>M</given-names></name><name><surname>Oepen</surname><given-names>G</given-names></name><name><surname>Botsch</surname><given-names>H</given-names></name><name><surname>Borchardt</surname><given-names>D</given-names></name><name><surname>Gouzoulis</surname><given-names>E</given-names></name><name><surname>Fehrenbach</surname><given-names>RA</given-names></name><name><surname>Spitzer</surname><given-names>M</given-names></name></person-group><article-title>Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research</article-title><source>Biological Psychiatry</source><year>1992</year><volume>32</volume><issue>11</issue><fpage>976</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">1467389</pub-id></element-citation></ref><ref id="R64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>E</given-names></name></person-group><article-title>Effects of a psychedelic, tropical tea, ayahuasca, on the electroencephalographic (EEG) activity of the human brain during a shamanistic ritual</article-title><source>MAPS Bulletin</source><year>2001</year><volume>11</volume><fpage>25</fpage><lpage>30</lpage></element-citation></ref><ref id="R65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holze</surname><given-names>F</given-names></name><name><surname>Ley</surname><given-names>L</given-names></name><name><surname>Müller</surname><given-names>F</given-names></name><name><surname>Becker</surname><given-names>AM</given-names></name><name><surname>Straumann</surname><given-names>I</given-names></name><name><surname>Vizeli</surname><given-names>P</given-names></name><name><surname>Kuehne</surname><given-names>SS</given-names></name><name><surname>Roder</surname><given-names>MA</given-names></name><name><surname>Duthaler</surname><given-names>U</given-names></name><name><surname>Kolaczynska</surname><given-names>KE</given-names></name><name><surname>Varghese</surname><given-names>N</given-names></name><etal/></person-group><article-title>Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects</article-title><source>Neuropsychopharmacology</source><year>2022</year><volume>47</volume><issue>6</issue><fpage>1180</fpage><lpage>1187</lpage><pub-id pub-id-type="pmcid">PMC9018810</pub-id><pub-id pub-id-type="pmid">35217796</pub-id><pub-id pub-id-type="doi">10.1038/s41386-022-01297-2</pub-id></element-citation></ref><ref id="R66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honey</surname><given-names>CJ</given-names></name><name><surname>Kötter</surname><given-names>R</given-names></name><name><surname>Breakspear</surname><given-names>M</given-names></name><name><surname>Sporns</surname><given-names>O</given-names></name></person-group><article-title>Network structure of cerebral cortex shapes functional connectivity on multiple time scales</article-title><source>Proceedings of the National Academy of Sciences</source><year>2007</year><volume>104</volume><issue>24</issue><fpage>10240</fpage><lpage>10245</lpage><pub-id pub-id-type="pmcid">PMC1891224</pub-id><pub-id pub-id-type="pmid">17548818</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0701519104</pub-id></element-citation></ref><ref id="R67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakab</surname><given-names>RL</given-names></name><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group><article-title>5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>1998</year><volume>95</volume><issue>2</issue><fpage>735</fpage><lpage>740</lpage><pub-id pub-id-type="pmcid">PMC18490</pub-id><pub-id pub-id-type="pmid">9435262</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.2.735</pub-id></element-citation></ref><ref id="R68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janowsky</surname><given-names>A</given-names></name><name><surname>Eshleman</surname><given-names>AJ</given-names></name><name><surname>Johnson</surname><given-names>RA</given-names></name><name><surname>Wolfrum</surname><given-names>KM</given-names></name><name><surname>Hinrichs</surname><given-names>DJ</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zabriskie</surname><given-names>TM</given-names></name><name><surname>Smilkstein</surname><given-names>MJ</given-names></name><name><surname>Riscoe</surname><given-names>MK</given-names></name></person-group><article-title>Mefloquine and Psychotomimetics Share Neurotransmitter Receptor and Transporter Interactions In Vitro</article-title><source>Psychopharmacology</source><year>2014</year><volume>231</volume><issue>14</issue><fpage>2771</fpage><lpage>2783</lpage><pub-id pub-id-type="pmcid">PMC4097020</pub-id><pub-id pub-id-type="pmid">24488404</pub-id><pub-id pub-id-type="doi">10.1007/s00213-014-3446-0</pub-id></element-citation></ref><ref id="R69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenakin</surname><given-names>T</given-names></name></person-group><article-title>A Scale of Agonism and Allosteric Modulation for Assessment of Selectivity, Bias, and Receptor Mutation</article-title><source>Molecular Pharmacology</source><year>2017</year><volume>92</volume><issue>4</issue><fpage>414</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">28679508</pub-id></element-citation></ref><ref id="R70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenakin</surname><given-names>T</given-names></name><name><surname>Watson</surname><given-names>C</given-names></name><name><surname>Muniz-Medina</surname><given-names>V</given-names></name><name><surname>Christopoulos</surname><given-names>A</given-names></name><name><surname>Novick</surname><given-names>S</given-names></name></person-group><article-title>A Simple Method for Quantifying Functional Selectivity and Agonist Bias</article-title><source>ACS Chemical Neuroscience</source><year>2011</year><volume>3</volume><issue>3</issue><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="pmcid">PMC3369801</pub-id><pub-id pub-id-type="pmid">22860188</pub-id><pub-id pub-id-type="doi">10.1021/cn200111m</pub-id></element-citation></ref><ref id="R71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozell</surname><given-names>LB</given-names></name><name><surname>Eshleman</surname><given-names>AJ</given-names></name><name><surname>Swanson</surname><given-names>TL</given-names></name><name><surname>Bloom</surname><given-names>SH</given-names></name><name><surname>Wolfrum</surname><given-names>KM</given-names></name><name><surname>Schmachtenberg</surname><given-names>JL</given-names></name><name><surname>Olson</surname><given-names>RJ</given-names></name><name><surname>Janowsky</surname><given-names>A</given-names></name><name><surname>Abbas</surname><given-names>AI</given-names></name></person-group><article-title>Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><year>2023</year><volume>385</volume><issue>1</issue><fpage>62</fpage><lpage>75</lpage><pub-id pub-id-type="pmcid">PMC10029822</pub-id><pub-id pub-id-type="pmid">36669875</pub-id><pub-id pub-id-type="doi">10.1124/jpet.122.001454</pub-id></element-citation></ref><ref id="R72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kringelbach</surname><given-names>ML</given-names></name><name><surname>Cruzat</surname><given-names>J</given-names></name><name><surname>Cabral</surname><given-names>J</given-names></name><name><surname>Knudsen</surname><given-names>GM</given-names></name><name><surname>Carhart-Harris</surname><given-names>R</given-names></name><name><surname>Whybrow</surname><given-names>PC</given-names></name><name><surname>Logothetis</surname><given-names>NK</given-names></name><name><surname>Deco</surname><given-names>G</given-names></name></person-group><article-title>Dynamic coupling of whole-brain neuronal and neurotransmitter systems</article-title><source>Proceedings of the National Academy of Sciences</source><year>2020</year><volume>117</volume><issue>17</issue><fpage>9566</fpage><lpage>9576</lpage><pub-id pub-id-type="pmcid">PMC7196827</pub-id><pub-id pub-id-type="pmid">32284420</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1921475117</pub-id></element-citation></ref><ref id="R73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kringelbach</surname><given-names>ML</given-names></name><name><surname>Deco</surname><given-names>G</given-names></name></person-group><article-title>Brain States and Transitions: Insights from Computational Neuroscience</article-title><source>Cell Reports</source><year>2020</year><volume>32</volume><issue>10</issue><elocation-id>108128</elocation-id><pub-id pub-id-type="pmid">32905760</pub-id></element-citation></ref><ref id="R74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawn</surname><given-names>T</given-names></name><name><surname>Dipasquale</surname><given-names>O</given-names></name><name><surname>Vamvakas</surname><given-names>A</given-names></name><name><surname>Tsougos</surname><given-names>I</given-names></name><name><surname>Mehta</surname><given-names>MA</given-names></name><name><surname>Howard</surname><given-names>MA</given-names></name></person-group><article-title>Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD</article-title><source>Psychopharmacology</source><year>2022</year><volume>239</volume><issue>6</issue><fpage>1797</fpage><lpage>1808</lpage><pub-id pub-id-type="pmcid">PMC9166846</pub-id><pub-id pub-id-type="pmid">35322297</pub-id><pub-id pub-id-type="doi">10.1007/s00213-022-06117-5</pub-id></element-citation></ref><ref id="R75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebedev</surname><given-names>AV</given-names></name><name><surname>Lövdén</surname><given-names>M</given-names></name><name><surname>Rosenthal</surname><given-names>G</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin</article-title><source>Human Brain Mapping</source><year>2015</year><volume>36</volume><issue>8</issue><fpage>3137</fpage><lpage>3153</lpage><pub-id pub-id-type="pmcid">PMC6869189</pub-id><pub-id pub-id-type="pmid">26010878</pub-id><pub-id pub-id-type="doi">10.1002/hbm.22833</pub-id></element-citation></ref><ref id="R76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Sehatpour</surname><given-names>P</given-names></name><name><surname>Hoptman</surname><given-names>MJ</given-names></name><name><surname>Lakatos</surname><given-names>P</given-names></name><name><surname>Dias</surname><given-names>EC</given-names></name><name><surname>Kantrowitz</surname><given-names>JT</given-names></name><name><surname>Martinez</surname><given-names>AM</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name></person-group><article-title>Neural mechanisms of mismatch negativity (MMN) dysfunction in schizophrenia</article-title><source>Molecular Psychiatry</source><year>2017</year><volume>22</volume><issue>11</issue><fpage>1585</fpage><lpage>1593</lpage><pub-id pub-id-type="pmcid">PMC5547016</pub-id><pub-id pub-id-type="pmid">28167837</pub-id><pub-id pub-id-type="doi">10.1038/mp.2017.3</pub-id></element-citation></ref><ref id="R77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>L</given-names></name><name><surname>Holze</surname><given-names>F</given-names></name><name><surname>Arikci</surname><given-names>D</given-names></name><name><surname>Becker</surname><given-names>AM</given-names></name><name><surname>Straumann</surname><given-names>I</given-names></name><name><surname>Klaiber</surname><given-names>A</given-names></name><name><surname>Coviello</surname><given-names>F</given-names></name><name><surname>Dierbach</surname><given-names>S</given-names></name><name><surname>Thomann</surname><given-names>J</given-names></name><name><surname>Duthaler</surname><given-names>U</given-names></name><name><surname>Luethi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants</article-title><source>Neuropsychopharmacology</source><year>2023</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmcid">PMC10517157</pub-id><pub-id pub-id-type="pmid">37231080</pub-id><pub-id pub-id-type="doi">10.1038/s41386-023-01607-2</pub-id></element-citation></ref><ref id="R78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López-Giménez</surname><given-names>JF</given-names></name><name><surname>González-Maeso</surname><given-names>J</given-names></name></person-group><article-title>Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways</article-title><source>Current Topics in Behavioral Neurosciences</source><year>2018</year><volume>36</volume><fpage>45</fpage><lpage>73</lpage><pub-id pub-id-type="pmcid">PMC5756147</pub-id><pub-id pub-id-type="pmid">28677096</pub-id><pub-id pub-id-type="doi">10.1007/7854_2017_478</pub-id></element-citation></ref><ref id="R79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>L</given-names></name><name><surname>Eckernäs</surname><given-names>E</given-names></name><name><surname>Ashton</surname><given-names>M</given-names></name><name><surname>Rosas</surname><given-names>F</given-names></name><name><surname>Uthaug</surname><given-names>M</given-names></name><name><surname>Bartha</surname><given-names>A</given-names></name><name><surname>Jagger</surname><given-names>S</given-names></name><name><surname>Gascon-Perai</surname><given-names>K</given-names></name><name><surname>Gomes</surname><given-names>L</given-names></name><name><surname>Nutt</surname><given-names>D</given-names></name><name><surname>Erritzoe</surname><given-names>D</given-names></name><etal/></person-group><article-title>Psychological and physiological effects of extended DMT</article-title><source>PsyArXiv</source><year>2023</year><pub-id pub-id-type="pmid">37897244</pub-id></element-citation></ref><ref id="R80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luppi</surname><given-names>AI</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Pappas</surname><given-names>I</given-names></name><name><surname>Menon</surname><given-names>DK</given-names></name><name><surname>Stamatakis</surname><given-names>EA</given-names></name></person-group><article-title>LSD alters dynamic integration and segregation in the human brain</article-title><source>NeuroImage</source><year>2021</year><volume>227</volume><elocation-id>117653</elocation-id><pub-id pub-id-type="pmcid">PMC7896102</pub-id><pub-id pub-id-type="pmid">33338615</pub-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117653</pub-id></element-citation></ref><ref id="R81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maclean</surname><given-names>KA</given-names></name><name><surname>Leoutsakos</surname><given-names>J-MS</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group><article-title>Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin</article-title><source>Journal for the Scientific Study of Religion</source><year>2012</year><volume>51</volume><issue>4</issue><fpage>721</fpage><lpage>737</lpage><pub-id pub-id-type="pmcid">PMC3539773</pub-id><pub-id pub-id-type="pmid">23316089</pub-id><pub-id pub-id-type="doi">10.1111/j.1468-5906.2012.01685.x</pub-id></element-citation></ref><ref id="R82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>MK</given-names></name><name><surname>Stenbæk</surname><given-names>DS</given-names></name><name><surname>Arvidsson</surname><given-names>A</given-names></name><name><surname>Armand</surname><given-names>S</given-names></name><name><surname>Marstrand-Joergensen</surname><given-names>MR</given-names></name><name><surname>Johansen</surname><given-names>SS</given-names></name><name><surname>Linnet</surname><given-names>K</given-names></name><name><surname>Ozenne</surname><given-names>B</given-names></name><name><surname>Knudsen</surname><given-names>GM</given-names></name><name><surname>Fisher</surname><given-names>PM</given-names></name></person-group><article-title>Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience</article-title><source>European Neuropsychopharmacology</source><year>2021</year><volume>50</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">34246868</pub-id></element-citation></ref><ref id="R83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertens</surname><given-names>LJ</given-names></name><name><surname>Wall</surname><given-names>MB</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Demetriou</surname><given-names>L</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression</article-title><source>Journal of Psychopharmacology (Oxford, England)</source><year>2020</year><volume>34</volume><issue>2</issue><fpage>167</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">31941394</pub-id></element-citation></ref><ref id="R84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molnar-Szakacs</surname><given-names>I</given-names></name><name><surname>Uddin</surname><given-names>L</given-names></name></person-group><article-title>Self-Processing and the Default Mode Network: Interactions with the Mirror Neuron System</article-title><source>Frontiers in Human Neuroscience</source><year>2013</year><volume>7</volume><pub-id pub-id-type="pmcid">PMC3769892</pub-id><pub-id pub-id-type="pmid">24062671</pub-id><pub-id pub-id-type="doi">10.3389/fnhum.2013.00571</pub-id></element-citation></ref><ref id="R85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>JM</given-names></name><name><surname>Kelley</surname><given-names>WM</given-names></name><name><surname>Heatherton</surname><given-names>TF</given-names></name></person-group><article-title>What Can the Organization of the Brain’s Default Mode Network Tell us About Self-Knowledge?</article-title><source>Frontiers in Human Neuroscience</source><year>2013</year><volume>7</volume><fpage>391</fpage><pub-id pub-id-type="pmcid">PMC3713343</pub-id><pub-id pub-id-type="pmid">23882210</pub-id><pub-id pub-id-type="doi">10.3389/fnhum.2013.00391</pub-id></element-citation></ref><ref id="R86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreton</surname><given-names>SG</given-names></name><name><surname>Szalla</surname><given-names>L</given-names></name><name><surname>Menzies</surname><given-names>RE</given-names></name><name><surname>Arena</surname><given-names>AF</given-names></name></person-group><article-title>Embedding existential psychology within psychedelic science: Reduced death anxiety as a mediator of the therapeutic effects of psychedelics</article-title><source>Psychopharmacology</source><year>2020</year><volume>237</volume><issue>1</issue><fpage>21</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">31784805</pub-id></element-citation></ref><ref id="R87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>F</given-names></name><name><surname>Dolder</surname><given-names>PC</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Borgwardt</surname><given-names>S</given-names></name></person-group><article-title>Altered network hub connectivity after acute LSD administration</article-title><source>NeuroImage Clinical</source><year>2018</year><volume>18</volume><fpage>694</fpage><lpage>701</lpage><pub-id pub-id-type="pmcid">PMC5857492</pub-id><pub-id pub-id-type="pmid">29560311</pub-id><pub-id pub-id-type="doi">10.1016/j.nicl.2018.03.005</pub-id></element-citation></ref><ref id="R88"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>F</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Lang</surname><given-names>UE</given-names></name><name><surname>Borgwardt</surname><given-names>S</given-names></name></person-group><chapter-title>Chapter 6 - Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain</chapter-title><person-group person-group-type="editor"><name><surname>Calvey</surname><given-names>T</given-names></name></person-group><source>Progress in Brain Research</source><publisher-name>Elsevier</publisher-name><year>2018</year><volume>242</volume><fpage>159</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">30471679</pub-id></element-citation></ref><ref id="R89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthukumaraswamy</surname><given-names>SD</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Moran</surname><given-names>RJ</given-names></name><name><surname>Brookes</surname><given-names>MJ</given-names></name><name><surname>Williams</surname><given-names>TM</given-names></name><name><surname>Errtizoe</surname><given-names>D</given-names></name><name><surname>Sessa</surname><given-names>B</given-names></name><name><surname>Papadopoulos</surname><given-names>A</given-names></name><name><surname>Bolstridge</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>KD</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><etal/></person-group><article-title>Broadband Cortical Desynchronization Underlies the Human Psychedelic State</article-title><source>Journal of Neuroscience</source><year>2013</year><volume>33</volume><issue>38</issue><fpage>15171</fpage><lpage>15183</lpage><pub-id pub-id-type="pmcid">PMC6618409</pub-id><pub-id pub-id-type="pmid">24048847</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2063-13.2013</pub-id></element-citation></ref><ref id="R90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muttoni</surname><given-names>S</given-names></name><name><surname>Ardissino</surname><given-names>M</given-names></name><name><surname>John</surname><given-names>C</given-names></name></person-group><article-title>Classical psychedelics for the treatment of depression and anxiety: A systematic review</article-title><source>Journal of Affective Disorders</source><year>2019</year><volume>258</volume><fpage>11</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">31382100</pub-id></element-citation></ref><ref id="R91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>DE</given-names></name></person-group><article-title>Hallucinogens</article-title><source>Pharmacology &amp; Therapeutics</source><year>2004</year><volume>101</volume><issue>2</issue><fpage>131</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">14761703</pub-id></element-citation></ref><ref id="R92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>DE</given-names></name></person-group><article-title>Psychedelics</article-title><source>Pharmacological Reviews</source><year>2016</year><volume>68</volume><issue>2</issue><fpage>264</fpage><lpage>355</lpage><pub-id pub-id-type="pmcid">PMC4813425</pub-id><pub-id pub-id-type="pmid">26841800</pub-id><pub-id pub-id-type="doi">10.1124/pr.115.011478</pub-id></element-citation></ref><ref id="R93"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>DE</given-names></name></person-group><chapter-title>Chemistry and Structure–Activity Relationships of Psychedelics</chapter-title><person-group person-group-type="editor"><name><surname>Halberstadt</surname><given-names>AL</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Nichols</surname><given-names>DE</given-names></name></person-group><source>Behavioral Neurobiology of Psychedelic Drugs</source><publisher-name>Springer</publisher-name><year>2018</year><fpage>1</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/7854_2017_475</pub-id></element-citation></ref><ref id="R94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nour</surname><given-names>MM</given-names></name><name><surname>Evans</surname><given-names>L</given-names></name><name><surname>Nutt</surname><given-names>D</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)</article-title><source>Frontiers in Human Neuroscience</source><year>2016</year><volume>10</volume><pub-id pub-id-type="pmcid">PMC4906025</pub-id><pub-id pub-id-type="pmid">27378878</pub-id><pub-id pub-id-type="doi">10.3389/fnhum.2016.00269</pub-id></element-citation></ref><ref id="R95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutt</surname><given-names>D</given-names></name><name><surname>Erritzoe</surname><given-names>D</given-names></name><name><surname>Carhart-Harris</surname><given-names>R</given-names></name></person-group><article-title>Psychedelic Psychiatry’s Brave New World</article-title><source>Cell</source><year>2020</year><volume>181</volume><issue>1</issue><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">32243793</pub-id></element-citation></ref><ref id="R96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pahnke</surname><given-names>WN</given-names></name></person-group><article-title>The Psychedelic Mystical Experience in the Human Encounter with Death*</article-title><source>Harvard Theological Review</source><year>1969</year><volume>62</volume><issue>1</issue><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1017/S0017816000027577</pub-id></element-citation></ref><ref id="R97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palhano-Fontes</surname><given-names>F</given-names></name><name><surname>Andrade</surname><given-names>KC</given-names></name><name><surname>Tofoli</surname><given-names>LF</given-names></name><name><surname>Santos</surname><given-names>AC</given-names></name><name><surname>Crippa</surname><given-names>JAS</given-names></name><name><surname>Hallak</surname><given-names>JEC</given-names></name><name><surname>Ribeiro</surname><given-names>S</given-names></name><name><surname>de Araujo</surname><given-names>DB</given-names></name></person-group><article-title>The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network</article-title><source>PLOS ONE</source><year>2015</year><volume>10</volume><issue>2</issue><elocation-id>e0118143</elocation-id><pub-id pub-id-type="pmcid">PMC4334486</pub-id><pub-id pub-id-type="pmid">25693169</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0118143</pub-id></element-citation></ref><ref id="R98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquini</surname><given-names>L</given-names></name><name><surname>Palhano-Fontes</surname><given-names>F</given-names></name><name><surname>Araujo</surname><given-names>DB</given-names></name></person-group><article-title>Subacute effects of the psychedelic ayahuasca on the salience and default mode networks</article-title><source>Journal of Psychopharmacology</source><year>2020</year><volume>34</volume><issue>6</issue><fpage>623</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">32255395</pub-id></element-citation></ref><ref id="R99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peill</surname><given-names>JM</given-names></name><name><surname>Trinci</surname><given-names>KE</given-names></name><name><surname>Kettner</surname><given-names>H</given-names></name><name><surname>Mertens</surname><given-names>LJ</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Timmermann</surname><given-names>C</given-names></name><name><surname>Rosas</surname><given-names>FE</given-names></name><name><surname>Lyons</surname><given-names>T</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience</article-title><source>Journal of Psychopharmacology (Oxford, England)</source><year>2022</year><volume>36</volume><issue>1</issue><fpage>31</fpage><lpage>45</lpage><pub-id pub-id-type="pmcid">PMC8801624</pub-id><pub-id pub-id-type="pmid">34983255</pub-id><pub-id pub-id-type="doi">10.1177/02698811211066709</pub-id></element-citation></ref><ref id="R100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>PA</given-names></name><name><surname>Peroutka</surname><given-names>SJ</given-names></name></person-group><article-title>Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex</article-title><source>Psychopharmacology</source><year>1989</year><volume>97</volume><issue>1</issue><fpage>118</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">2540505</pub-id></element-citation></ref><ref id="R101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pokorny</surname><given-names>T</given-names></name><name><surname>Preller</surname><given-names>KH</given-names></name><name><surname>Kraehenmann</surname><given-names>R</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience</article-title><source>European Neuropsychopharmacology</source><year>2016</year><volume>26</volume><issue>4</issue><fpage>756</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">26875114</pub-id></element-citation></ref><ref id="R102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pottie</surname><given-names>E</given-names></name><name><surname>Cannaert</surname><given-names>A</given-names></name><name><surname>Stove</surname><given-names>CP</given-names></name></person-group><article-title>In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor</article-title><source>Archives of Toxicology</source><year>2020</year><volume>94</volume><issue>10</issue><fpage>3449</fpage><lpage>3460</lpage><pub-id pub-id-type="pmid">32627074</pub-id></element-citation></ref><ref id="R103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pottie</surname><given-names>E</given-names></name><name><surname>Dedecker</surname><given-names>P</given-names></name><name><surname>Stove</surname><given-names>CP</given-names></name></person-group><article-title>Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays</article-title><source>Biochemical Pharmacology</source><year>2020</year><volume>182</volume><elocation-id>114251</elocation-id><pub-id pub-id-type="pmid">32998000</pub-id></element-citation></ref><ref id="R104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preller</surname><given-names>KH</given-names></name><name><surname>Herdener</surname><given-names>M</given-names></name><name><surname>Pokorny</surname><given-names>T</given-names></name><name><surname>Planzer</surname><given-names>A</given-names></name><name><surname>Kraehenmann</surname><given-names>R</given-names></name><name><surname>Stämpfli</surname><given-names>P</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Seifritz</surname><given-names>E</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation</article-title><source>Current Biology: CB</source><year>2017</year><volume>27</volume><issue>3</issue><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">28132813</pub-id></element-citation></ref><ref id="R105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puig</surname><given-names>MV</given-names></name><name><surname>Celada</surname><given-names>P</given-names></name><name><surname>Díaz-Mataix</surname><given-names>L</given-names></name><name><surname>Artigas</surname><given-names>F</given-names></name></person-group><article-title>In Vivo Modulation of the Activity of Pyramidal Neurons in the Rat Medial Prefrontal Cortex by 5-HT2A Receptors: Relationship to Thalamocortical Afferents</article-title><source>Cerebral Cortex</source><year>2003</year><volume>13</volume><issue>8</issue><fpage>870</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">12853374</pub-id></element-citation></ref><ref id="R106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>T(Tim)</given-names></name><name><surname>Minda</surname><given-names>JP</given-names></name></person-group><article-title>Recreational Psychedelic Users Frequently Encounter Complete Mystical Experiences: Trip Content and Implications for Wellbeing</article-title><source>PsyArXiv</source><year>2021</year><pub-id pub-id-type="doi">10.31234/osf.io/xrbzs</pub-id></element-citation></ref><ref id="R107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Kometer</surname><given-names>M</given-names></name><name><surname>Geyer</surname><given-names>MA</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers</article-title><source>Neuropsychopharmacology</source><year>2012</year><volume>37</volume><issue>3</issue><comment>Article 3</comment><pub-id pub-id-type="pmcid">PMC3260978</pub-id><pub-id pub-id-type="pmid">21956447</pub-id><pub-id pub-id-type="doi">10.1038/npp.2011.228</pub-id></element-citation></ref><ref id="R108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riba</surname><given-names>J</given-names></name><name><surname>Anderer</surname><given-names>P</given-names></name><name><surname>Jané</surname><given-names>F</given-names></name><name><surname>Saletu</surname><given-names>B</given-names></name><name><surname>Barbanoj</surname><given-names>MJ</given-names></name></person-group><article-title>Effects of the South American Psychoactive Beverage Ayahuasca on Regional Brain Electrical Activity in Humans: A Functional Neuroimaging Study Using Low-Resolution Electromagnetic Tomography</article-title><source>Neuropsychobiology</source><year>2004</year><volume>50</volume><issue>1</issue><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">15179026</pub-id></element-citation></ref><ref id="R109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riba</surname><given-names>J</given-names></name><name><surname>Anderer</surname><given-names>P</given-names></name><name><surname>Morte</surname><given-names>A</given-names></name><name><surname>Urbano</surname><given-names>G</given-names></name><name><surname>Jané</surname><given-names>F</given-names></name><name><surname>Saletu</surname><given-names>B</given-names></name><name><surname>Barbanoj</surname><given-names>MJ</given-names></name></person-group><article-title>Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers</article-title><source>British Journal of Clinical Pharmacology</source><year>2002</year><volume>53</volume><issue>6</issue><fpage>613</fpage><lpage>628</lpage><pub-id pub-id-type="pmcid">PMC1874340</pub-id><pub-id pub-id-type="pmid">12047486</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2125.2002.01609.x</pub-id></element-citation></ref><ref id="R110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riba</surname><given-names>J</given-names></name><name><surname>Rodríguez-Fornells</surname><given-names>A</given-names></name><name><surname>Barbanoj</surname><given-names>MJ</given-names></name></person-group><article-title>Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively</article-title><source>Psychopharmacology</source><year>2002</year><volume>165</volume><issue>1</issue><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">12474114</pub-id></element-citation></ref><ref id="R111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickli</surname><given-names>A</given-names></name><name><surname>Moning</surname><given-names>OD</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens</article-title><source>European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology</source><year>2016</year><volume>26</volume><issue>8</issue><fpage>1327</fpage><lpage>1337</lpage><pub-id pub-id-type="pmid">27216487</pub-id></element-citation></ref><ref id="R112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguiz</surname><given-names>RM</given-names></name><name><surname>Nadkarni</surname><given-names>V</given-names></name><name><surname>Means</surname><given-names>CR</given-names></name><name><surname>Pogorelov</surname><given-names>VM</given-names></name><name><surname>Chiu</surname><given-names>Y-T</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name><name><surname>Wetsel</surname><given-names>WC</given-names></name></person-group><article-title>LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1</article-title><source>Scientific Reports</source><year>2021</year><volume>11</volume><issue>1</issue><comment>Article 1</comment><pub-id pub-id-type="pmcid">PMC8417039</pub-id><pub-id pub-id-type="pmid">34480046</pub-id><pub-id pub-id-type="doi">10.1038/s41598-021-96736-3</pub-id></element-citation></ref><ref id="R113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Demetriou</surname><given-names>L</given-names></name><name><surname>Wall</surname><given-names>MB</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression</article-title><source>Neuropharmacology</source><year>2018</year><volume>142</volume><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">29288686</pub-id></element-citation></ref><ref id="R114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Haijen</surname><given-names>E</given-names></name><name><surname>Idialu-Ikato</surname><given-names>K</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Watts</surname><given-names>R</given-names></name><name><surname>Carhart-Harris</surname><given-names>R</given-names></name></person-group><article-title>Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory</article-title><source>Journal of Psychopharmacology (Oxford, England)</source><year>2019</year><volume>33</volume><issue>9</issue><fpage>1076</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">31294673</pub-id></element-citation></ref><ref id="R115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers</article-title><source>Frontiers in Human Neuroscience</source><year>2014</year><volume>8</volume><pub-id pub-id-type="pmcid">PMC4034428</pub-id><pub-id pub-id-type="pmid">24904346</pub-id><pub-id pub-id-type="doi">10.3389/fnhum.2014.00204</pub-id></element-citation></ref><ref id="R116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz</surname><given-names>C</given-names></name><name><surname>Zamberlan</surname><given-names>F</given-names></name><name><surname>Erowid</surname><given-names>E</given-names></name><name><surname>Erowid</surname><given-names>F</given-names></name><name><surname>Tagliazucchi</surname><given-names>E</given-names></name></person-group><article-title>The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports</article-title><source>Frontiers in Neuroscience</source><year>2018</year><volume>12</volume><pub-id pub-id-type="pmcid">PMC5786560</pub-id><pub-id pub-id-type="pmid">29403350</pub-id><pub-id pub-id-type="doi">10.3389/fnins.2018.00007</pub-id></element-citation></ref><ref id="R117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>GP</given-names></name><name><surname>Jain</surname><given-names>MK</given-names></name><name><surname>Slocum</surname><given-names>ST</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name></person-group><article-title>5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics</article-title><source>ACS Chemical Neuroscience</source><year>2022</year><volume>13</volume><issue>16</issue><fpage>2386</fpage><lpage>2398</lpage><pub-id pub-id-type="pmid">35894503</pub-id></element-citation></ref><ref id="R118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrantee</surname><given-names>A</given-names></name><name><surname>Ferguson</surname><given-names>B</given-names></name><name><surname>Stoffers</surname><given-names>D</given-names></name><name><surname>Booij</surname><given-names>J</given-names></name><name><surname>Rombouts</surname><given-names>S</given-names></name><name><surname>Reneman</surname><given-names>L</given-names></name></person-group><article-title>Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls</article-title><source>Brain Imaging and Behavior</source><year>2016</year><volume>10</volume><issue>2</issue><fpage>548</fpage><lpage>558</lpage><pub-id pub-id-type="pmcid">PMC4908160</pub-id><pub-id pub-id-type="pmid">26149196</pub-id><pub-id pub-id-type="doi">10.1007/s11682-015-9419-z</pub-id></element-citation></ref><ref id="R119"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>U</given-names></name><name><surname>Pincas</surname><given-names>H</given-names></name><name><surname>Sealfon</surname><given-names>SC</given-names></name><name><surname>González-Maeso</surname><given-names>J</given-names></name></person-group><chapter-title>Chapter 11—Structure and function of serotonin GPCR heteromers</chapter-title><person-group person-group-type="editor"><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Cunningham</surname><given-names>KA</given-names></name></person-group><source>Handbook of Behavioral Neuroscience</source><publisher-name>Elsevier</publisher-name><year>2020</year><volume>31</volume><fpage>217</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-64125-0.00011-6</pub-id></element-citation></ref><ref id="R120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smigielski</surname><given-names>L</given-names></name><name><surname>Scheidegger</surname><given-names>M</given-names></name><name><surname>Kometer</surname><given-names>M</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects</article-title><source>NeuroImage</source><year>2019</year><volume>196</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">30965131</pub-id></element-citation></ref><ref id="R121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruston</surname><given-names>N</given-names></name></person-group><article-title>Pyramidal neurons: Dendritic structure and synaptic integration</article-title><source>Nature Reviews Neuroscience</source><year>2008</year><volume>9</volume><issue>3</issue><comment>Article 3</comment><pub-id pub-id-type="pmid">18270515</pub-id></element-citation></ref><ref id="R122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>W</given-names></name></person-group><article-title>Lysergsaure-diathylamid, ein Phantastikum aus der Mutterkorngruppe</article-title><source>Royal Society of Medicine, Microfilm Unit</source><year>1947</year></element-citation></ref><ref id="R123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strassman</surname><given-names>RJ</given-names></name><name><surname>Qualls</surname><given-names>CR</given-names></name></person-group><article-title>Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects</article-title><source>Archives of General Psychiatry</source><year>1994</year><volume>51</volume><issue>2</issue><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">8297216</pub-id></element-citation></ref><ref id="R124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strassman</surname><given-names>RJ</given-names></name><name><surname>Qualls</surname><given-names>CR</given-names></name><name><surname>Uhlenhuth</surname><given-names>EH</given-names></name><name><surname>Kellner</surname><given-names>R</given-names></name></person-group><article-title>Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale</article-title><source>Archives of General Psychiatry</source><year>1994</year><volume>51</volume><issue>2</issue><fpage>98</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">8297217</pub-id></element-citation></ref><ref id="R125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuckey</surname><given-names>DE</given-names></name><name><surname>Lawson</surname><given-names>R</given-names></name><name><surname>Luna</surname><given-names>LE</given-names></name></person-group><article-title>EEG gamma coherence and other correlates of subjective reports during ayahuasca experiences</article-title><source>Journal of Psychoactive Drugs</source><year>2005</year><volume>37</volume><issue>2</issue><fpage>163</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">16149330</pub-id></element-citation></ref><ref id="R126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studerus</surname><given-names>E</given-names></name><name><surname>Gamma</surname><given-names>A</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)</article-title><source>PLOS ONE</source><year>2010</year><volume>5</volume><issue>8</issue><elocation-id>e12412</elocation-id><pub-id pub-id-type="pmcid">PMC2930851</pub-id><pub-id pub-id-type="pmid">20824211</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0012412</pub-id></element-citation></ref><ref id="R127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sykes</surname><given-names>DA</given-names></name><name><surname>Stoddart</surname><given-names>LA</given-names></name><name><surname>Kilpatrick</surname><given-names>LE</given-names></name><name><surname>Hill</surname><given-names>SJ</given-names></name></person-group><article-title>Binding kinetics of ligands acting at GPCRs</article-title><source>Molecular and Cellular Endocrinology</source><year>2019</year><volume>485</volume><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="pmcid">PMC6406023</pub-id><pub-id pub-id-type="pmid">30738950</pub-id><pub-id pub-id-type="doi">10.1016/j.mce.2019.01.018</pub-id></element-citation></ref><ref id="R128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagliazucchi</surname><given-names>E</given-names></name></person-group><article-title>Early and Contemporary Human Neuroimaging Studies of Serotonergic Psychedelics</article-title><year>2020</year><pub-id pub-id-type="doi">10.20944/preprints202005.0510.v1</pub-id></element-citation></ref><ref id="R129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagliazucchi</surname><given-names>E</given-names></name><name><surname>Carhart-Harris</surname><given-names>R</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>Nutt</surname><given-names>D</given-names></name><name><surname>Chialvo</surname><given-names>DR</given-names></name></person-group><article-title>Enhanced repertoire of brain dynamical states during the psychedelic experience</article-title><source>Human Brain Mapping</source><year>2014</year><volume>35</volume><issue>11</issue><fpage>5442</fpage><lpage>5456</lpage><pub-id pub-id-type="pmcid">PMC6869695</pub-id><pub-id pub-id-type="pmid">24989126</pub-id><pub-id pub-id-type="doi">10.1002/hbm.22562</pub-id></element-citation></ref><ref id="R130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagliazucchi</surname><given-names>E</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Orban</surname><given-names>C</given-names></name><name><surname>Muthukumaraswamy</surname><given-names>SD</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Laufs</surname><given-names>H</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>McGonigle</surname><given-names>J</given-names></name><name><surname>Crossley</surname><given-names>N</given-names></name><name><surname>Bullmore</surname><given-names>E</given-names></name><etal/></person-group><article-title>Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution</article-title><source>Current Biology: CB</source><year>2016</year><volume>26</volume><issue>8</issue><fpage>1043</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">27085214</pub-id></element-citation></ref><ref id="R131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas Yeo</surname><given-names>BT</given-names></name><name><surname>Krienen</surname><given-names>FM</given-names></name><name><surname>Sepulcre</surname><given-names>J</given-names></name><name><surname>Sabuncu</surname><given-names>MR</given-names></name><name><surname>Lashkari</surname><given-names>D</given-names></name><name><surname>Hollinshead</surname><given-names>M</given-names></name><name><surname>Roffman</surname><given-names>JL</given-names></name><name><surname>Smoller</surname><given-names>JW</given-names></name><name><surname>Zöllei</surname><given-names>L</given-names></name><name><surname>Polimeni</surname><given-names>JR</given-names></name><name><surname>Fischl</surname><given-names>B</given-names></name><etal/></person-group><article-title>The organization of the human cerebral cortex estimated by intrinsic functional connectivity</article-title><source>Journal of Neurophysiology</source><year>2011</year><volume>106</volume><issue>3</issue><fpage>1125</fpage><lpage>1165</lpage><pub-id pub-id-type="pmcid">PMC3174820</pub-id><pub-id pub-id-type="pmid">21653723</pub-id><pub-id pub-id-type="doi">10.1152/jn.00338.2011</pub-id></element-citation></ref><ref id="R132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmermann</surname><given-names>C</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Haridas</surname><given-names>S</given-names></name><name><surname>Rosas</surname><given-names>FE</given-names></name><name><surname>Luan</surname><given-names>L</given-names></name><name><surname>Kettner</surname><given-names>H</given-names></name><name><surname>Martell</surname><given-names>J</given-names></name><name><surname>Erritzoe</surname><given-names>D</given-names></name><name><surname>Tagliazucchi</surname><given-names>E</given-names></name><name><surname>Pallavicini</surname><given-names>C</given-names></name><name><surname>Girn</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human brain effects of DMT assessed via EEG-fMRI</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2023</year><volume>120</volume><issue>13</issue><elocation-id>e2218949120</elocation-id><pub-id pub-id-type="pmcid">PMC10068756</pub-id><pub-id pub-id-type="pmid">36940333</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2218949120</pub-id></element-citation></ref><ref id="R133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmermann</surname><given-names>C</given-names></name><name><surname>Spriggs</surname><given-names>MJ</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Moran</surname><given-names>RJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Muthukumaraswamy</surname><given-names>SD</given-names></name></person-group><article-title>LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm</article-title><source>Neuropharmacology</source><year>2018</year><volume>142</volume><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">29101022</pub-id></element-citation></ref><ref id="R134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tófoli</surname><given-names>LF</given-names></name><name><surname>de Araujo</surname><given-names>DB</given-names></name></person-group><article-title>Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics</article-title><source>International Review of Neurobiology</source><year>2016</year><volume>129</volume><fpage>157</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">27503452</pub-id></element-citation></ref><ref id="R135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tupper</surname><given-names>KW</given-names></name><name><surname>Wood</surname><given-names>E</given-names></name><name><surname>Yensen</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name></person-group><article-title>Psychedelic medicine: A re-emerging therapeutic paradigm</article-title><source>CMAJ : Canadian Medical Association Journal</source><year>2015</year><volume>187</volume><issue>14</issue><fpage>1054</fpage><lpage>1059</lpage><pub-id pub-id-type="pmcid">PMC4592297</pub-id><pub-id pub-id-type="pmid">26350908</pub-id><pub-id pub-id-type="doi">10.1503/cmaj.141124</pub-id></element-citation></ref><ref id="R136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuteja</surname><given-names>N</given-names></name></person-group><article-title>Signaling through G protein coupled receptors</article-title><source>Plant Signaling &amp; Behavior</source><year>2009</year><volume>4</volume><issue>10</issue><fpage>942</fpage><lpage>947</lpage><pub-id pub-id-type="pmcid">PMC2801357</pub-id><pub-id pub-id-type="pmid">19826234</pub-id><pub-id pub-id-type="doi">10.4161/psb.4.10.9530</pub-id></element-citation></ref><ref id="R137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umbricht</surname><given-names>D</given-names></name><name><surname>Koller</surname><given-names>R</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Schmid</surname><given-names>L</given-names></name></person-group><article-title>Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers</article-title><source>Biological Psychiatry</source><year>2002</year><volume>51</volume><issue>5</issue><fpage>400</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">11904134</pub-id></element-citation></ref><ref id="R138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umbricht</surname><given-names>D</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Schmid</surname><given-names>L</given-names></name><name><surname>Grübel</surname><given-names>C</given-names></name><name><surname>Skrabo</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>T</given-names></name><name><surname>Koller</surname><given-names>R</given-names></name></person-group><article-title>Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia</article-title><source>Neuropsychopharmacology</source><year>2003</year><volume>28</volume><issue>1</issue><comment>Article 1</comment><pub-id pub-id-type="pmid">12496954</pub-id></element-citation></ref><ref id="R139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Buuren</surname><given-names>M</given-names></name><name><surname>Gladwin</surname><given-names>TE</given-names></name><name><surname>Zandbelt</surname><given-names>BB</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name><name><surname>Vink</surname><given-names>M</given-names></name></person-group><article-title>Reduced functional coupling in the default‐mode network during self‐referential processing</article-title><source>Human Brain Mapping</source><year>2010</year><volume>31</volume><issue>8</issue><fpage>1117</fpage><lpage>1127</lpage><pub-id pub-id-type="pmcid">PMC6870730</pub-id><pub-id pub-id-type="pmid">20108218</pub-id><pub-id pub-id-type="doi">10.1002/hbm.20920</pub-id></element-citation></ref><ref id="R140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Essen</surname><given-names>DC</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Barch</surname><given-names>DM</given-names></name><name><surname>Behrens</surname><given-names>TEJ</given-names></name><name><surname>Yacoub</surname><given-names>E</given-names></name><name><surname>Ugurbil</surname><given-names>K</given-names></name></person-group><article-title>The WU-Minn Human Connectome Project: An overview</article-title><source>NeuroImage</source><year>2013</year><volume>80</volume><fpage>62</fpage><lpage>79</lpage><pub-id pub-id-type="pmcid">PMC3724347</pub-id><pub-id pub-id-type="pmid">23684880</pub-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.05.041</pub-id></element-citation></ref><ref id="R141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogt</surname><given-names>SB</given-names></name><name><surname>Ley</surname><given-names>L</given-names></name><name><surname>Erne</surname><given-names>L</given-names></name><name><surname>Straumann</surname><given-names>I</given-names></name><name><surname>Becker</surname><given-names>AM</given-names></name><name><surname>Klaiber</surname><given-names>A</given-names></name><name><surname>Holze</surname><given-names>F</given-names></name><name><surname>Vandersmissen</surname><given-names>A</given-names></name><name><surname>Mueller</surname><given-names>L</given-names></name><name><surname>Duthaler</surname><given-names>U</given-names></name><name><surname>Rudin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants</article-title><source>Translational Psychiatry</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>172</fpage><pub-id pub-id-type="pmcid">PMC10206108</pub-id><pub-id pub-id-type="pmid">37221177</pub-id><pub-id pub-id-type="doi">10.1038/s41398-023-02477-4</pub-id></element-citation></ref><ref id="R142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Csomor</surname><given-names>PA</given-names></name><name><surname>Knappe</surname><given-names>B</given-names></name><name><surname>Geyer</surname><given-names>MA</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name></person-group><article-title>The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval</article-title><source>Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology</source><year>2007</year><volume>32</volume><issue>9</issue><fpage>1876</fpage><lpage>1887</lpage><pub-id pub-id-type="pmid">17299516</pub-id></element-citation></ref><ref id="R143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Leenders</surname><given-names>KL</given-names></name><name><surname>Scharfetter</surname><given-names>C</given-names></name><name><surname>Maguire</surname><given-names>P</given-names></name><name><surname>Stadelmann</surname><given-names>O</given-names></name><name><surname>Angst</surname><given-names>J</given-names></name></person-group><article-title>Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis</article-title><source>Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology</source><year>1997</year><volume>16</volume><issue>5</issue><fpage>357</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">9109107</pub-id></element-citation></ref><ref id="R144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Vollenweider-Scherpenhuyzen</surname><given-names>MF</given-names></name><name><surname>Bäbler</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Hell</surname><given-names>D</given-names></name></person-group><article-title>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action</article-title><source>Neuroreport</source><year>1998</year><volume>9</volume><issue>17</issue><fpage>3897</fpage><lpage>3902</lpage><pub-id pub-id-type="pmid">9875725</pub-id></element-citation></ref><ref id="R145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Vontobel</surname><given-names>P</given-names></name><name><surname>Hell</surname><given-names>D</given-names></name><name><surname>Leenders</surname><given-names>KL</given-names></name></person-group><article-title>5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride</article-title><source>Neuropsychopharmacology</source><year>1999</year><volume>20</volume><issue>5</issue><comment>Article 5</comment><pub-id pub-id-type="pmid">10192823</pub-id></element-citation></ref><ref id="R146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vossel</surname><given-names>S</given-names></name><name><surname>Geng</surname><given-names>JJ</given-names></name><name><surname>Fink</surname><given-names>GR</given-names></name></person-group><article-title>Dorsal and Ventral Attention Systems</article-title><source>The Neuroscientist</source><year>2014</year><volume>20</volume><issue>2</issue><fpage>150</fpage><lpage>159</lpage><pub-id pub-id-type="pmcid">PMC4107817</pub-id><pub-id pub-id-type="pmid">23835449</pub-id><pub-id pub-id-type="doi">10.1177/1073858413494269</pub-id></element-citation></ref><ref id="R147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>MB</given-names></name><name><surname>Lam</surname><given-names>C</given-names></name><name><surname>Ertl</surname><given-names>N</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>Increased low-frequency brain responses to music after psilocybin therapy for depression</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.02.13.480302</elocation-id><pub-id pub-id-type="pmid">37094657</pub-id></element-citation></ref><ref id="R148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallach</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>AB</given-names></name><name><surname>Calkins</surname><given-names>MM</given-names></name><name><surname>Heim</surname><given-names>AJ</given-names></name><name><surname>Lanham</surname><given-names>JK</given-names></name><name><surname>Bonniwell</surname><given-names>EM</given-names></name><name><surname>Hennessey</surname><given-names>JJ</given-names></name><name><surname>Bock</surname><given-names>HA</given-names></name><name><surname>Anderson</surname><given-names>EI</given-names></name><name><surname>Sherwood</surname><given-names>AM</given-names></name><name><surname>Morris</surname><given-names>H</given-names></name><etal/></person-group><article-title>Identification of 5-HT2A Receptor Signaling Pathways Responsible for Psychedelic Potential</article-title><source>bioRxiv</source><year>2023</year><elocation-id>2023.07.29.551106</elocation-id><pub-id pub-id-type="pmcid">PMC10724237</pub-id><pub-id pub-id-type="pmid">38102107</pub-id><pub-id pub-id-type="doi">10.1038/s41467-023-44016-1</pub-id></element-citation></ref><ref id="R149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>VJ</given-names></name><name><surname>Lawler</surname><given-names>CP</given-names></name><name><surname>Fox</surname><given-names>DR</given-names></name><name><surname>Neve</surname><given-names>KA</given-names></name><name><surname>Nichols</surname><given-names>DE</given-names></name><name><surname>Mailman</surname><given-names>RB</given-names></name></person-group><article-title>LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors</article-title><source>Psychopharmacology</source><year>1995</year><volume>118</volume><issue>4</issue><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">7568626</pub-id></element-citation></ref><ref id="R150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>AM</given-names></name><name><surname>Soreni</surname><given-names>N</given-names></name><name><surname>Noseworthy</surname><given-names>MD</given-names></name></person-group><article-title>A preliminary study on the effects of acute ethanol ingestion on default mode network and temporal fractal properties of the brain</article-title><source>Magma (New York NY)</source><year>2014</year><volume>27</volume><issue>4</issue><fpage>291</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">24287715</pub-id></element-citation></ref><ref id="R151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><article-title>BrainNet Viewer: A Network Visualization Tool for Human Brain Connectomics</article-title><source>PLOS ONE</source><year>2013</year><volume>8</volume><issue>7</issue><elocation-id>e68910</elocation-id><pub-id pub-id-type="pmcid">PMC3701683</pub-id><pub-id pub-id-type="pmid">23861951</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0068910</pub-id></element-citation></ref><ref id="R152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaden</surname><given-names>DB</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Doss</surname><given-names>MK</given-names></name><name><surname>Garcia-Romeu</surname><given-names>A</given-names></name><name><surname>Nayak</surname><given-names>S</given-names></name><name><surname>Gukasyan</surname><given-names>N</given-names></name><name><surname>Mathur</surname><given-names>BN</given-names></name><name><surname>Barrett</surname><given-names>FS</given-names></name></person-group><article-title>Psychedelics and consciousness: Distinctions, demarcations, and opportunities</article-title><source>International Journal of Neuropsychopharmacology</source><year>2021</year><volume>24</volume><issue>8</issue><fpage>615</fpage><lpage>623</lpage><pub-id pub-id-type="pmcid">PMC8378075</pub-id><pub-id pub-id-type="pmid">33987652</pub-id><pub-id pub-id-type="doi">10.1093/ijnp/pyab026</pub-id></element-citation></ref><ref id="R153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamberlan</surname><given-names>F</given-names></name><name><surname>Sanz</surname><given-names>C</given-names></name><name><surname>Martínez Vivot</surname><given-names>R</given-names></name><name><surname>Pallavicini</surname><given-names>C</given-names></name><name><surname>Erowid</surname><given-names>F</given-names></name><name><surname>Erowid</surname><given-names>E</given-names></name><name><surname>Tagliazucchi</surname><given-names>E</given-names></name></person-group><article-title>The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines</article-title><source>Frontiers in Integrative Neuroscience</source><year>2018</year><volume>12</volume><fpage>54</fpage><pub-id pub-id-type="pmcid">PMC6235949</pub-id><pub-id pub-id-type="pmid">30467466</pub-id><pub-id pub-id-type="doi">10.3389/fnint.2018.00054</pub-id></element-citation></ref><ref id="R154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>Brain default-mode network dysfunction in addiction</article-title><source>NeuroImage</source><year>2019</year><volume>200</volume><fpage>313</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">31229660</pub-id></element-citation></ref><ref id="R155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H-X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>Y-Q</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>N-X</given-names></name><name><surname>Zhu</surname><given-names>Z-C</given-names></name><name><surname>Castellanos</surname><given-names>FX</given-names></name><name><surname>Yan</surname><given-names>C-G</given-names></name></person-group><article-title>Rumination and the default mode network: Meta-analysis of brain imaging studies and implications for depression</article-title><source>NeuroImage</source><year>2020</year><volume>206</volume><elocation-id>116287</elocation-id><pub-id pub-id-type="pmid">31655111</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Meta-analysis of the 5-Dimensional Altered States of Consciousness (5D-ASC) data reveals only one significant difference between psychedelics, but many more significant differences within psychedelics.</title><p>The 5D-ASC is one of the most commonly used scales for subjective reports of psychedelic experiences. It measures altered states of consciousness along five different dimensions: oceanic boundlessness (OB; a feeling of interconnectedness), anxious ego dissolution (AED), visionary restructuralisation (VR; the quality and intensity of visual hallucinations), auditory alterations (AA), and reduction of vigilance (RV). Our literature search identified 23 studies that reported 5D-ASC data. We performed a three-level random-effects meta-analysis, where the third level consisted of studies that reported multiple data points corresponding to different doses given to the same group of participants; this analysis thereby accounted for the lack of statistical independence among the inputs. Within-study and between-study heterogeneity were estimated with the restricted maximum likelihood procedure. Using a Correlated and Hierarchical Effects model to account for within-study correlations in sampling error, we performed meta-regressions to analyse the effect of dose and drug (DMT, LSD, or psilocybin) on pooled 5D-ASC scores. DMT was administered intravenously in phenomenological studies, whereas LSD and psilocybin were administered orally. Thus, DMT has different pharmacokinetics from LSD and psilocybin, which impacts the subjective experience, so we only compared significant between-drug differences for LSD and psilocybin. We only compared the two drugs for similar doses, assuming that 0.1 mg LSD = 20 mg psilocybin (<xref ref-type="bibr" rid="R77">Ley et al., 2023</xref>). (a-c, left column) Between-drug comparisons of pooled 5D-ASC scores for LSD and psilocybin. LSD almost always ranked higher than psilocybin, but differences only reached significance in the VR dimension for high and medium doses and in the OB dimension for medium dose. (a-c, right column) Within-drug comparisons for LSD and psilocybin. VR, OB, and RV received much higher scores than AED and AA. (d-e) Within-drug comparisons for DMT. At low doses, OB and VR ranked significantly higher than AED. Only one study measured ASC scores for the AA and RV dimensions on DMT, so we did not perform a meta-analysis on these dimensions for DMT. Numerical data for the above figure are given in <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>. We also conducted a meta-analysis of the 11-dimensional ASC scale, which is also widely used in the literature; the results are displayed in <xref ref-type="supplementary-material" rid="SD1">Figure S3 and Table S2</xref>. * &lt; 0.05, ** &lt; 0.01, *** &lt; 0.001.</p></caption><graphic xlink:href="EMS189365-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Phenomenology profiles of the psychedelics demonstrate broad similarity between the neural correlates of their phenomenology.</title><p>We identified 14 studies that measured correlations between ASC ratings and fMRI activity or pairwise connectivity, including three studies on ketamine. We determined the Yeo network that contained each brain region that exhibited a significant correlation, and then we averaged across the correlations associated with each Yeo network, resulting in the mean correlation between each Yeo network and each ASC scale. The phenomenology profiles were defined by a weighted combination of the mean correlations for each ASC scale, in which the weights were the pooled ASC ratings of each psychedelic for the corresponding scale. Because the pooled ASC ratings are similar across psychedelics, the phenomenology profiles are very alike one another as well. However, the lack of data on the neural correlates of the ASC ratings limits our confidence in the validity of these profiles.</p></caption><graphic xlink:href="EMS189365-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Meta-analysis of the functional connectivity (FC) data indicates increases in between-network connectivity and decreases in within-network connectivity.</title><p>To perform a meta-analysis on the FC data, we determined the Yeo networks that contained each pair of functionally connected regions of interest (ROIs) in the literature and then performed a weighted sum of the number of significant connections between Yeo networks. We included n = 12 studies in this meta-analysis, after excluding studies that did not measure pairwise FC and secondary analyses of identical datasets. (a) Aggregate FC matrix, in which each entry contains the overall connectivity between a pair of Yeo networks. (b) Blacked-out values are statistically insignificant (p &gt; 0.05) with respect to a null distribution formed from resting-state Human Connectome Project data. (c) A rendering of the statistically significant FC scores on the surface of the brain. Insignificant edges are red, and significant edges are yellow. Images produced through the BrainNet Viewer (<xref ref-type="bibr" rid="R151">Xia et al., 2013</xref>).</p></caption><graphic xlink:href="EMS189365-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Functional connectivity (FC) profiles show unique FC patterns for each psychedelic.</title><p>Out of the n = 12 studies that we examined in our quantitative FC meta-analysis, n = 3 were studies on ayahuasca/DMT (ayahuasca: n = 2; DMT: n = 1), n = 3 on LSD, and n = 6 on psilocybin. Each FC profile contains the total FC of each network, which was obtained by taking the normalised sum of the rows of the corresponding aggregate FC matrices, including insignificant values. (The units of the profiles are arbitrary.) The psychedelics display distinct FC profiles; for instance, ayahuasca and DMT increase total FC for the DMN more strongly than for other networks, whereas LSD elevates FC more for the SMN and DAN than for other networks.</p></caption><graphic xlink:href="EMS189365-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Pharmacology meta-analysis reveals that there are no significant differences in selectivity between psychedelics and that LSD induces significantly higher relative activity at the inositol phosphate (IP) formation pathway.</title><p>For both the selectivity and relative activity data, we created random-effects models that modeled between-study variance, with drugs included as covariates. (a) Selectivity is the ratio between the binding affinity (measured as Ki) for a receptor of interest and the affinity for a reference receptor. We measured selectivity for three different receptors, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, and D<sub>2</sub>, relative to 5-HT<sub>1A</sub>. Our literature search identified n = 14 studies on selectivity, including n = 6 studies on DMT, n = 9 studies on LSD, and n = 5 studies on psilocin. We did not find any significant between-drug differences in selectivity for any of the three receptors. (b) Relative activity is Δlog(E<sub>max</sub>/EC<sub>50</sub>), where E<sub>max</sub> is the maximal effect of the drug relative to a reference ligand and EC<sub>50</sub> is the concentration needed to elicit 50% of the maximal response. The log of the ratio is measured for both the drug and the reference ligand, and then the difference is taken (<xref ref-type="bibr" rid="R69">Kenakin, 2017</xref>). We found n = 18 studies on functional activity, including n = 6 studies on DMT, n = 13 studies on LSD, and n = 6 studies on psilocin. We measured relative activity at three different signaling pathways: calcium mobilisation, IP formation, and β-arrestin2 recruitment. IP formation was the only pathway that exhibited any significant between-drug differences; LSD elicited significantly higher activity than both DMT and psilocin.</p></caption><graphic xlink:href="EMS189365-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Pharmacology profiles reveal that psilocin binds with (insignificantly) higher specificity to the 5-HT<sub>2A</sub> receptor than DMT and LSD do.</title><p>Based on an available PET atlas of the 5-HT<sub>2A</sub> and D<sub>2</sub> receptors (<xref ref-type="bibr" rid="R59">Hansen et al., 2022</xref>), we created the pharmacology profile of each psychedelic. The profiles show the expression of those two receptors in the Yeo networks, weighted by the specificity of the corresponding psychedelics. The PET atlas reveals that the 5-HT<sub>2A</sub> receptor is expressed much more in the human brain than the D<sub>2</sub> receptor. Therefore, the profiles are dominated by 5-HT<sub>2A</sub> receptor expression. Since psilocin has the most specificity for 5-HT<sub>2A</sub> (relative to 5-HT<sub>1A</sub>), followed by LSD, psilocin’s pharmacology profile is the most extensive.</p></caption><graphic xlink:href="EMS189365-f006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><title>The hierarchy of psychedelic effects highlights the nonlinear relationship between pharmacology, neuroimaging, and phenomenology.</title><p>The effects of psychedelics form a tripartite hierarchy, consisting of subjective experience (a, phenomenology), functional connectivity (b, neuroimaging), and their selective affinity for receptors (c, pharmacology). Here, we show the neural correlates of each level of the hierarchy in the seven Yeo networks. In brief, each profile was derived from (a) neural correlates of the subjective dimensions of the ASC scale, (b) summing th aggregate FC between each network and other networks, and (c) multiplying the affinities with each receptor’s density in each Yeo network. Clearly, there is a very weak correspondence between the different levels of the hierarchy, revealing the highly non-linear relationship between phenomenology, neuroimaging, and pharmacology. Note: we analysed data on DMT in our phenomenology and pharmacology meta-analyses and data on both DMT and ayahuasca in our FC meta-analysis. We examined data on psilocin in our pharmacology meta-analysis and on psilocybin in both of the other meta-analyses.</p></caption><graphic xlink:href="EMS189365-f007"/></fig></floats-group></article>